
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2014

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____

Commission file number: 001-36272



(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

37-1744899
(I.R.S. Employer Identification No.)

5200 Blue Lagoon Drive, Suite 855
Miami, Florida
(Address of principal executive offices)

33126
(Zip Code)

Registrant's telephone number, including area code: (203) 575-5850

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-Accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practical date.

Class
Common Stock, par value \$0.01 per share

August 1, 2014
137,300,222 shares

Table of Contents

| Part I. | Financial Information | Page |
|-----------------------------------|--|---------------------------|
| <u>Item 1.</u> | <u>Financial Statements</u> | <u>3</u> |
| <u>Item 2.</u> | <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>28</u> |
| <u>Item 3.</u> | <u>Quantitative and Qualitative Disclosures About Market Risk</u> | <u>36</u> |
| <u>Item 4.</u> | <u>Controls and Procedures</u> | <u>37</u> |
| <hr/> | | |
| Part II. | Other Information | |
| <u>Item 1.</u> | <u>Legal Proceedings</u> | <u>37</u> |
| <u>Item 1A.</u> | <u>Risk Factors</u> | <u>37</u> |
| <u>Item 2.</u> | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | <u>39</u> |
| <u>Item 3.</u> | <u>Defaults Upon Senior Securities</u> | <u>39</u> |
| <u>Item 4.</u> | <u>Mine Safety Disclosures</u> | <u>39</u> |
| <u>Item 5.</u> | <u>Other Information</u> | <u>39</u> |
| <u>Item 6.</u> | <u>Exhibits</u> | <u>40</u> |
| <u>Signatures</u> | | <u>41</u> |

Part I. Financial Information

Item 1. Financial Statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share amounts)

| | For the three months ended June 30, 2014 | Period from Inception (April 23, 2013) through June 30, 2013 | For the three months ended June 30, 2013 | For the six months ended June 30, 2014 | Period from Inception (April 23, 2013) through June 30, 2013 | For the six months ended June 30, 2013 |
|---|---|---|---|---|---|---|
| | <i>Successor</i> | <i>Successor</i> | <i>Predecessor</i> | <i>Successor</i> | <i>Successor</i> | <i>Predecessor</i> |
| Net sales | \$ 189,132 | \$ - | \$ 189,992 | \$ 372,858 | \$ - | \$ 372,124 |
| Cost of sales | 92,445 | - | 93,451 | 191,949 | - | 182,269 |
| Gross profit | 96,687 | - | 96,541 | 180,909 | - | 189,855 |
| Operating expenses: | | | | | | |
| Selling, technical, general and administrative | 84,779 | 97 | 53,989 | 158,811 | 97 | 109,969 |
| Research and development | 5,898 | - | 5,874 | 12,096 | - | 11,826 |
| Restructuring | 404 | - | 46 | 404 | - | 1,652 |
| Total operating expenses | 91,081 | 97 | 59,909 | 171,311 | 97 | 123,447 |
| Operating profit (loss) | 5,606 | (97) | 36,632 | 9,598 | (97) | 66,408 |
| Other (expense) income: | | | | | | |
| Interest, net | (7,662) | 17 | (12,849) | (15,404) | - | (24,567) |
| Loss on extinguishment of debt | - | - | (18,788) | - | - | (18,788) |
| Other (expense) income, net | (512) | - | (2,999) | (601) | 17 | 588 |
| | (8,174) | 17 | (34,636) | (16,005) | 17 | (42,767) |
| (Loss) income before income taxes, non- controlling interests and accrued payment-in- kind dividends on cumulative preferred shares | (2,568) | (80) | 1,996 | (6,407) | (80) | 23,641 |
| Income tax benefit (provision) | 4,056 | - | (7,760) | 1,947 | - | (14,068) |
| Net income (loss) | 1,488 | (80) | (5,764) | (4,460) | (80) | 9,573 |
| Net income attributable to the non-controlling interests | (1,864) | - | (91) | (3,334) | - | (180) |
| Net (loss) income attributable to common shareholders | (376) | (80) | (5,855) | (7,794) | (80) | 9,393 |
| Accrued payment-in-kind dividend on cumulative preferred shares | - | - | (9,278) | - | - | (21,072) |
| Net loss attributable to common shares | \$ (376) | \$ (80) | \$ (15,133) | \$ (7,794) | \$ (80) | \$ (11,679) |
| Earnings (loss) per share | | | | | | |
| Basic | \$ (0.00) | \$ (0.00) | n/a | \$ (0.07) | \$ (0.00) | n/a |
| Diluted | \$ (0.00) | \$ (0.00) | n/a | \$ (0.07) | \$ (0.00) | n/a |
| Weighted average shares outstanding (In thousands) | | | | | | |
| Basic | 128,595 | 88,529 | n/a | 117,937 | 88,529 | n/a |
| Diluted | 128,595 | 88,529 | n/a | 117,937 | 88,529 | n/a |

See accompanying notes to condensed consolidated financial statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(In thousands)

| | Period from Inception (April 23, 2013) | | Period from Inception (April 23, 2013) | | | |
|--|---|---|---|---|---------|---|
| | For the three months ended June 30, 2014 <i>Successor</i> | through June 30, 2013 <i>Successor</i> | For the three months ended June 30, 2013 <i>Predecessor</i> | For the six months ended June 30, 2014 <i>Successor</i> | | through June 30, 2013 <i>Successor</i> |
| Net income (loss) | \$ 1,488 | \$ (80) | \$ (5,764) | \$ (4,460) | \$ (80) | \$ 9,573 |
| Other comprehensive income (loss) income, before tax | | | | | | |
| Foreign currency translation adjustments | 19,688 | - | (5,453) | 22,975 | - | (22,009) |
| Unrealized (loss) gain on available for sale securities | 57 | - | (96) | 6 | - | 49 |
| Pension and postretirement plan | - | - | - | 217 | - | - |
| Derivative financial instruments revaluation | (178) | - | 130 | (163) | - | (650) |
| Total other comprehensive income (loss), before tax | 19,567 | - | (5,419) | 23,035 | - | (22,610) |
| Income tax benefit (provision) on comprehensive income (loss) | 53 | - | (12) | 72 | - | 210 |
| Other comprehensive income (loss), net of tax | 19,620 | - | (5,431) | 23,107 | - | (22,400) |
| Comprehensive income attributable to the non-controlling interests | (3,209) | - | (91) | (4,674) | - | (148) |
| Comprehensive income (loss) attributable to common shareholders | \$ 17,899 | \$ (80) | \$ (11,286) | \$ 13,973 | \$ (80) | \$ (12,975) |

See accompanying notes to condensed consolidated financial statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and per share amounts)

| | June 30, 2014 | December 31, 2013 |
|---|---------------------|---------------------|
| Assets | | |
| Cash & cash equivalents | \$ 642,760 | \$ 123,040 |
| Accounts receivable, net of allowance for doubtful accounts of \$10,430 and \$10,113 at June 30, 2014 and December 31, 2013, respectively | 142,011 | 140,525 |
| Inventories | 80,511 | 89,618 |
| Prepaid expenses & other current assets | 24,262 | 30,269 |
| Total current assets | 889,544 | 383,452 |
| Property, plant & equipment, net | 133,641 | 136,166 |
| Goodwill | 1,004,354 | 989,808 |
| Intangible assets, net | 699,443 | 720,302 |
| Other assets | 39,707 | 30,426 |
| Total assets | <u>\$ 2,766,689</u> | <u>\$ 2,260,154</u> |
| Liabilities & Stockholders' Equity | | |
| Accounts payable | 56,990 | 56,156 |
| Accrued salaries, wages and employee benefits | 17,136 | 22,656 |
| Current installments of long-term debt | 7,953 | 7,958 |
| Accrued income taxes payable | 3,434 | 6,669 |
| Accrued expenses and other current liabilities | 29,812 | 26,234 |
| Total current liabilities | 115,325 | 119,673 |
| Long-term debt | 740,497 | 744,291 |
| Long-term retirement benefits, less current portion | 23,812 | 25,129 |
| Long-term deferred income taxes | 166,298 | 169,800 |
| Long-term contingent consideration | 58,600 | 34,800 |
| Other long-term liabilities | 35,956 | 30,387 |
| Total liabilities | 1,140,488 | 1,124,080 |
| Commitments and contingencies (Note 13) | | |
| Redeemable 401(k) plan interest | - | 20,972 |
| Stockholders' Equity | | |
| Preferred shares (2,000,000 designated as Series A), 5,000,000 shares authorized, 2,000,000 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively | 20 | - |
| Common shares, \$0.01 par value (effective January 23, 2014), 400,000,000 shares authorized, 137,290,980 and 103,571,941 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively | 1,353 | - |
| Additional paid-in capital | 1,703,483 | 1,212,038 |
| Accumulated deficit | (202,016) | (194,222) |
| Accumulated other comprehensive income | 24,372 | 1,265 |
| Total stockholders equity | 1,527,212 | 1,019,081 |
| Non-controlling interests | 98,989 | 96,021 |
| Total equity | 1,626,201 | 1,115,102 |
| Total liabilities, redeemable 401(k) plan interest and stockholders' equity | <u>\$ 2,766,689</u> | <u>\$ 2,260,154</u> |

See accompanying notes to condensed consolidated financial statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)

| | <u>For the six months ended June 30, 2014</u> | <u>Period from Inception (April 23, 2013) through June 30, 2013</u> | <u>For the six months ended June 30, 2013</u> |
|--|---|---|---|
| | <i>Successor</i> | <i>Successor</i> | <i>Predecessor</i> |
| Cash flows from operating activities: | | | |
| Net (loss) income | \$ (4,460) | \$ (80) | \$ 9,573 |
| Adjustments to reconcile net (loss) income from operations to net cash flows provided by operating activities: | | | |
| Depreciation and amortization | 38,286 | - | 19,741 |
| Deferred income taxes | (13,801) | - | 4,954 |
| Non-cash fair value adjustment to contingent consideration | 23,800 | - | - |
| Manufacturer's profit in inventory adjustment | 11,956 | - | - |
| Loss on extinguishment of debt | - | - | 18,788 |
| Other, net | 1,568 | 27 | 3,153 |
| Changes in assets & liabilities, net of acquisitions: | | | |
| Accounts receivable | (1,990) | - | (10,620) |
| Inventories | (1,700) | - | (2,818) |
| Accrued expenses | (5,415) | - | (3,351) |
| Other assets and liabilities | 970 | (2) | (2,173) |
| Net cash flows provided by (used in) operating activities | 49,214 | (55) | 37,247 |
| Cash flows from investing activities: | | | |
| Capital expenditures, net | (4,587) | - | (3,687) |
| Purchases of marketable securities | - | (359,933) | - |
| Acquisition of business, net | 4,827 | - | - |
| Other, net | - | - | 1,057 |
| Net cash flows provided by (used in) investing activities | 240 | (359,933) | (2,630) |
| Cash flows from financing activities: | | | |
| Proceeds from issuance of debt, net of discount and fees | - | - | 1,109,513 |
| Repayments of borrowings | (3,795) | - | (624,396) |
| Repurchase of Predecessor Series A preferred stock | - | - | (270,167) |
| Payment of Predecessor Series A preferred stock | - | - | (229,833) |
| Escrowed funds for debt repayment | - | - | (105,864) |
| Proceeds from issuance of common stock, net | 473,625 | 861,218 | - |
| Proceeds from issuance of preferred stock, net | - | 20,000 | - |
| Payment of debt financing fees | - | - | (12,571) |
| Other, net | 136 | - | (287) |
| Net cash flows provided by (used in) financing activities | 469,966 | 881,218 | (133,605) |
| Effect of exchange rate changes on cash and cash equivalents | 300 | - | (1,455) |
| Net increase (decrease) in cash and cash equivalents | 519,720 | 521,230 | (100,443) |
| Cash and cash equivalents at beginning of period | 123,040 | - | 143,351 |
| Cash and cash equivalents at end of period | <u>\$ 642,760</u> | <u>\$ 521,230</u> | <u>\$ 42,908</u> |

See accompanying notes to condensed consolidated financial statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Platform Specialty Products Corporation and its subsidiaries (“Platform,” the “Company,” “we” or “us”) (formerly named Platform Acquisition Holdings Limited) is a global producer of high-technology specialty chemical products and provider of technical services and currently operates through its indirect subsidiary, MacDermid, Incorporated (“MacDermid” or the “Predecessor”). Platform was originally incorporated with limited liability under the laws of the British Virgin Islands under the BVI Companies Act on April 23, 2013. Until its acquisition of MacDermid on October 31, 2013, the Company had neither engaged in any operations nor generated any income. The Company selected December 31 as its fiscal year end.

On October 31, 2013, Platform indirectly acquired substantially all of the equity of, MacDermid Holdings, LLC (“MacDermid Holdings”), which owned approximately 97% of MacDermid (the “MacDermid Acquisition”). As a result, Platform became a holding company for the MacDermid business. We acquired the remaining 3% of MacDermid on March 4, 2014, pursuant to the terms of an Exchange Agreement, dated October 25, 2013, between us and the fiduciaries of the MacDermid, Incorporated Profit Sharing and Employee Savings Plan (the “MacDermid Savings Plan”). Concurrently with the closing of the MacDermid Acquisition, we changed our name to Platform Specialty Products Corporation. On January 22, 2014, we changed our jurisdiction of incorporation from the British Virgin Islands to Delaware (the “Domestication”) and on January 23, 2014, our shares of common stock, par value \$0.01 per share (“Common Stock”) began trading on the New York Stock Exchange (“NYSE”) under the ticker symbol “PAH”.

The accompanying unaudited condensed consolidated interim financial statements and related information included herein are (1) for Platform as of June 30, 2014 and December 31, 2013 and for the period from April 1, 2014 through June 30, 2014 (the “Successor Quarterly Period”) and January 1, 2014 through June 30, 2014 (the “Successor Six Month Period”), (2) for Platform, prior to the completion of the MacDermid Acquisition, for the period from Inception (April 23, 2013) through June 30, 2013 (the “Platform Preacquisition Period”), and (3) for MacDermid for the period from April 1, 2013 through June 30, 2013 (the “Predecessor Quarterly Period”) and January 1, 2013 through June 30, 2013 (the “Predecessor Six Month Period”).

These unaudited condensed consolidated interim financial statements and related information have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements reflect all adjustments that are, in the opinion of management, normal and recurring and necessary for a fair statement of the results of operations. These unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and the related notes thereto included in the Company’s latest Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

Certain reclassifications and revisions have been made to the Consolidated Balance Sheet at December 31, 2013 and corresponding disclosures in accordance with Financial Accounting Standards Board (the “FASB”) ASC Topic 805, “*Business Combinations*” to reflect retrospective purchase accounting adjustments to the preliminary estimated fair values of certain assets acquired and liabilities assumed upon completion of the MacDermid Acquisition in addition to accumulated other comprehensive income. See Note 2 – “Acquisitions of Businesses” for further discussion.”

Accounting Policies Recently Adopted and Pending Pronouncements

In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, “*Revenue from Contracts with Customers (Topic 606)*” which 1) removes inconsistencies and weaknesses in revenue requirements, 2) provides a more robust framework for addressing revenue issues, 3) improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, 4) provides more useful information to users of financial statements through improved disclosure requirements and 5) simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2016. The Company is in the process of evaluating the impact of this new ASU.

In March 2013, the FASB issued ASU No. 2013-05, “*Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity, (a consensus of the FASB Emerging Issues Task Force)*” which resolves diversity in practice regarding the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investments in a foreign entity. In addition, the standard resolves diversity in practice for the treatment of business combinations achieved in stages involving a foreign entity. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2013. The adoption of this new ASU did not have a material impact on our consolidated financial position, results of operations or cash flows in the Successor Quarterly or Six Month Periods.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

2. ACQUISITIONS OF BUSINESSES

MacDermid Acquisition

On October 31, 2013, the Company completed the MacDermid Acquisition. The total consideration paid in connection with the MacDermid Acquisition and the acquisition of the approximately 3% of MacDermid equity interests (the "MacDermid Plan Shares") not already held by MacDermid Holdings was approximately \$1,800,000 (including the assumption of approximately \$754,200 of indebtedness), plus (i) up to \$100,000 of contingent consideration tied to achievement of EBITDA and stock trading price performance metrics over a seven-year period following the closing of the MacDermid Acquisition and (ii) an interest in certain MacDermid pending litigation. As a result of a favorable adjustment to the preliminary estimated working capital factored into the purchase price, the Company received a payment of approximately \$8,540 in January 2014 which is reflected in "Acquisition of business, net" in the accompanying Condensed Consolidated Statements of Cash Flows.

The fair value of contingent consideration was measured based on significant inputs not observable in the market, which are considered to be Level 3 inputs under the FASB ASC Topic 820 fair value hierarchy (see Note 10 - "Fair Value Measurements"). Key assumptions included in the fair value calculation of the EBITDA related earnout include a discount rate of approximately 2% and expected future value of payments of \$60,000 calculated using a probability weighted EBITDA assessment with higher probability associated with the Company achieving the maximum EBITDA targets. Key assumptions included in the fair value calculation of the stock price related earnout include the fair value of Common Stock, the expected future value of payments of \$40,000 and an assumption of volatility. The stock price related earnout was calculated using a Monte Carlo simulation. At the time of the MacDermid Acquisition, the fair value of the contingent payments was \$35,500. As of June 30, 2014 and December 31, 2013, the fair value of the contingent consideration was \$58,600 and \$34,800, respectively, which was included in "Other long-term liabilities" in the accompanying Condensed Consolidated Balance Sheets. The \$10,800 and \$23,800 increase in fair value during the Successor Quarterly and Six Month Periods, respectively, which is recorded in "Selling, technical, general and administrative expenses" in the accompanying Condensed Consolidated Statements of Operations, was primarily due to the achievement of certain stock trading price performance metric targets of the contingent consideration arrangement.

During the Successor Quarterly Period, the Company revised its allocations of the purchase price as follows:

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

| Purchase Price Allocation (in thousands): | Original | Revised | Revision |
|--|---------------------|---------------------|-----------------|
| Preliminary value assigned: | | | |
| Accounts receivable | \$ 147,400 | \$ 147,400 | \$ - |
| Inventories | 115,300 | 115,300 | - |
| Other current assets | 26,200 | 26,200 | - |
| Property, plant and equipment | 142,800 | 140,900 | (1,900) |
| Customer relationships | 458,400 | 494,000 | 35,600 |
| Developed technology | 155,000 | 164,200 | 9,200 |
| Tradenames | 73,400 | 70,800 | (2,600) |
| Goodwill | 993,800 | 990,000 | (3,800) |
| Other assets | 30,800 | 28,300 | (2,500) |
| Accounts payable | (55,900) | (55,900) | - |
| Other current liabilities | (62,100) | (62,000) | 100 |
| Long-term debt | (754,200) | (754,200) | - |
| Non-current deferred tax liability | (140,700) | (171,200) | (30,500) |
| Contingent consideration | (35,500) | (35,500) | - |
| Redeemable 401(k) plan interest | (21,000) | (21,000) | - |
| Other liabilities | (66,500) | (66,500) | - |
| Total purchase price | <u>\$ 1,007,200</u> | <u>\$ 1,010,800</u> | <u>\$ 3,600</u> |

The measurement period adjustments described above had a cumulative \$1,500 impact to amortization expense which was recorded in the Successor Quarterly Period as the impact on prior periods was not material.

Immediately prior to the closing of the MacDermid Acquisition, certain sellers of MacDermid, including certain officers of MacDermid (each, a “Retaining Holder”), executed a Retaining Holder Securityholders’ Agreement (a “RHSA”) with the Company pursuant to which they agreed to exchange their equity in MacDermid for equity in our subsidiary, Platform Delaware Holdings, Inc. (“PDH”), at an exchange rate of \$11.00 per shares plus, (i) a proportionate share of the \$100,000 contingent consideration described above and (ii) an interest in certain MacDermid pending litigation. This 6.76% ownership has been accounted for as a non-controlling interest in the Company’s financial statements. The Retaining Holders can exchange up to 25% of shares for Platform Common Stock beginning on November 1, 2014. The number of potential shares of Common Stock issuable upon the exchange is approximately 8.8 million. This equity is classified as a “Non-controlling interest” in the accompanying Condensed Consolidated Balance Sheets.

Upon the closing of the MacDermid Acquisition, the MacDermid Savings Plan retained a 3% interest in MacDermid. The fair value of the obligation to purchase these shares of \$20,972 was recorded as a redeemable 401(k) interest in the mezzanine section of the Consolidated Balance Sheets at December 31, 2013 since it could be settled in either cash or stock. On March 4, 2014, pursuant to the terms of an Exchange Agreement, dated October 25, 2013, between the Company and the fiduciaries of the MacDermid Savings Plan, the Company acquired the remaining approximately 3% of the MacDermid Plan Shares for approximately \$2,600 in cash (which is reflected in “Acquisition of business, net” in the accompanying Condensed Consolidated Statements of Cash Flows) and 1,670,386 shares of the Company’s Common Stock.

Chemtura Acquisition

On April 16, 2014, Platform entered into a Stock and Asset Purchase Agreement with Chemtura Corporation, a Delaware corporation (“Chemtura,” and together with certain of its subsidiaries, the “Sellers”) pursuant to which Platform agreed to acquire the Sellers’ agrochemicals business, Chemtura AgroSolutions, consisting of the manufacture, distribution, marketing and sale of seed treatments and crop protection in niche markets across seven major product lines – seed treatments, insecticides, miticides, herbicides, fungicides, plant growth regulators and adjuvants, for approximately \$1,000,000, consisting of \$950,000 in cash, subject to working capital and other adjustments, 2,000,000 shares of Common Stock and the assumption of certain liabilities by Platform (the “Chemtura Acquisition”). The closing of the Chemtura Acquisition is subject to the satisfaction or waiver of certain customary and other closing conditions for transactions of this type, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and approvals of government authorities. Subsequent to Platform’s announcement of the Chemtura Acquisition, Platform’s cash on hand position improved, primarily as a result of a private placement completed on May 21, 2014 (the “Private Placement”). See Note 11 – “Stockholders’ Equity” for more information. As a result, the Company deposited \$315,000 into an escrow account on July 3, 2014, which is restricted to the financing of the Chemtura Acquisition, and entered into an amended and restated debt commitment letter. See Note 8 – “Debt” for more information. In connection with the Chemtura Acquisition, the Company incurred approximately \$9,900 in related expenses in the Successor Quarterly Period that are included in Selling, technical, general and administrative expenses in the Condensed Consolidated Statement of Operations. The Company is also committed to pay an additional \$5,000 in finder’s fees upon the closing of the Chemtura Acquisition.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

Other

During the quarter ended March 31, 2012, MacDermid acquired 95% of the stock of a specialty chemical business in Brazil for a total purchase price of \$8,900. This business was acquired to complement the service and product offerings within Brazil and its balance sheet and results of operations have been included in the Performance Materials segment. During the first quarter of 2014, the remaining \$1,114 purchase price was paid.

3. INVENTORIES

The major components of inventory were as follows:

| | <u>June 30, 2014</u> | <u>December 31, 2013</u> |
|----------------------------|----------------------|--------------------------|
| Finished goods | \$ 49,880 | \$ 58,360 |
| Raw materials and supplies | 28,761 | 29,870 |
| Equipment | 1,870 | 1,388 |
| Total inventory, net | <u>\$ 80,511</u> | <u>\$ 89,618</u> |

In connection with the MacDermid Acquisition, the fair value assessment of inventory resulted in an increase to finished goods of \$35,868. During the Successor Period ended December 31, 2013, \$23,992 was charged to cost of sales in the Consolidated Statement of Operations and \$11,956 was charged to cost of sales in the Condensed Consolidated Statement of Operations during the three months ended March 31, 2014 based on our estimated inventory turnover.

4. PROPERTY, PLANT AND EQUIPMENT

The major components of property, plant and equipment were as follows:

| | <u>June 30, 2014</u> | <u>December 31, 2013</u> |
|------------------------------------|----------------------|--------------------------|
| Land and leasehold improvements | \$ 27,860 | \$ 29,946 |
| Buildings and improvements | 36,290 | 38,914 |
| Machinery, equipment and fixtures | 73,424 | 63,475 |
| | 137,574 | 132,335 |
| Less: accumulated depreciation | <u>(14,202)</u> | <u>(3,900)</u> |
| | 123,372 | 128,435 |
| Construction in process | 10,269 | 7,731 |
| Property, plant and equipment, net | <u>\$ 133,641</u> | <u>\$ 136,166</u> |

Depreciation expense of \$5,392 and \$3,162 was recorded during the Successor Quarterly Period and Predecessor Quarterly Period, respectively. Depreciation expense of \$8,965 and \$6,314 was recorded during the Successor Six Month Period and Predecessor Six Month Period, respectively. There was no depreciation expense recorded for the Platform Preacquisition Period.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

5. GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by segment are as follows:

| | Performance Materials | Graphic Solutions | Total |
|--|----------------------------------|------------------------------|---------------------|
| Balance, December 31, 2013 | \$ 760,371 | \$ 229,437 | \$ 989,808 |
| Foreign currency translation and other | 14,089 | 457 | 14,546 |
| Balance, June 30, 2014 | <u>\$ 774,460</u> | <u>\$ 229,894</u> | <u>\$ 1,004,354</u> |

The carrying value of indefinite-lived intangible assets other than goodwill which consist solely of tradenames was \$71,033 and \$70,913 at June 30, 2014 and December 31, 2013, respectively.

Intangible assets subject to amortization were as follows:

| | June 30, 2014 | | | December 31, 2013 | | |
|----------------------|--------------------------------------|--|---------------------------|--------------------------------------|--|---------------------------|
| | Gross Carrying Amount | Accumulated Amortization and Foreign Exchange | Net Book Value | Gross Carrying Amount | Accumulated Amortization and Foreign Exchange | Net Book Value |
| Customer lists | \$ 494,000 | \$ (19,600) | \$ 474,400 | \$ 494,000 | \$ (6,420) | \$ 487,580 |
| Developed technology | 164,200 | (10,190) | 154,010 | 164,200 | (2,391) | 161,809 |
| Total | <u>\$ 658,200</u> | <u>\$ (29,790)</u> | <u>\$ 628,410</u> | <u>\$ 658,200</u> | <u>\$ (8,811)</u> | <u>\$ 649,389</u> |

Customer relationships have useful lives ranging from 8 to 20 years and developed technology has useful lives ranging between 7 to 10 years. This results in weighted average useful lives for customer relationships and developed technology, of approximately 16 years and 10 years, respectively, for an aggregate weighted average useful life of approximately 15 years at June 30, 2014.

Amortization expense of \$16,004 and \$6,692 was recorded during the Successor Quarterly Period and Predecessor Quarterly Period, respectively. Amortization expense of \$29,321 and \$13,427 was recorded during Successor Six Month Period and Predecessor Six Month Period, respectively. There was no amortization expense recorded for the Platform Preacquisition Period.

6. EQUITY COMPENSATION PLANS

Successor Period

On June 12, 2014, the Company's stockholders approved the Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (the "2013 Plan"). At June 30, 2014, the total number of shares of Common Stock of our Company that may be subject to the granting of awards under the 2013 Plan based on the grants issued as discussed below is approximately 15,088,000 shares.

On March 6, 2014, the Board of Directors (the "Board") approved a grant of 329,823 restricted stock units ("RSUs"), effective on June 12, 2014 with approval of the 2013 Plan, to certain employees that cliff vest on December 31, 2020. The RSUs are subject to an EBTIDA performance condition and a share price market condition that are similar in terms to those discussed in Note 2 – "Acquisitions of Businesses" related to the contingent consideration arrangement. Additionally, the number of shares of Common Stock to be issued is limited to a maximum cash value, requiring these awards to be classified as liabilities. The combined undiscounted maximum cash value of all RSU's issued is approximately \$7,100 which will be recognized as compensation expense through the vesting date. Compensation expense associated with these awards for the three and six month periods ended June 30, 2014 was approximately \$92.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

On March 6, 2014, the Board approved a grant of 9,242 RSUs to directors of the Company, effective on June 12, 2014 with approval of the 2013 Plan, that immediately vested. Compensation expense of \$262 associated with these awards was fully recognized in the three and six month periods ended June 30, 2014. On July 31, 2014 such RSUs were settled in shares of Common Stock and issued to the directors.

On May 3, 2014, the Board approved a grant of 72,500 RSUs to certain employees of the Company, effective on June 12, 2014 with approval of the 2013 Plan, with a weighted average grant-date fair value per share of \$28.36. Approximately 69% of these RSUs vest on the date on which the Company files its financial statement on Form 10-K for the year ending December 31, 2019, while the remainder will vest under similar terms for the year ending December 31, 2017. The RSUs are subject to an EBTIDA performance condition that must be achieved in the final vesting year. Compensation expense associated with these awards for the three and six month period ended June 30, 2014 was approximately \$41.

Effective March 6, 2014, the Board adopted the Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan (the "ESPP"), which was approved by the Company's stockholders on June 12, 2014. The Board approved a maximum of 5,178,815 shares of Common Stock, which were reserved and made available for issuance under the ESPP. As of June 30, 2014, no shares have been issued under the ESPP.

Predecessor Period

On January 29, 2013, the Predecessor authorized for issuance 5,000,000 Class C Junior Shares. The Class C Junior Shares were allocated to three tranches of 1,666,666 shares each and defined as Class C-1 Junior Shares, Class C-2 Junior Shares and Class C-3 Junior Shares (collectively, "C Shares"). The Class C-1 Junior Shares vested upon the grant date of January 29, 2013. Class C-2 Junior Shares were to vest on January 1, 2014 and the Class C-3 Junior Shares were to vest on January 1, 2015. The number of issued and awarded Class C Junior Shares was 4,890,000 shares or 1,630,000 shares each for the Class C-1 Junior Shares, Class C-2 Junior Shares and Class C-3 Junior Shares. The value of the C Shares was measured based upon the performance criteria in the operating agreement of MacDermid Holdings based on the estimated equity value of the Predecessor. The C Shares were to be paid in cash in accordance with the operating agreement of MacDermid Holdings upon a change in control, liquidating event or initial public offering. Payment for the C shares required continued employment through a change in control, liquidating event, or initial public offering. The C Shares were considered liability-classified awards with the related fair value recognized as compensation expense ratably over the performance period, with changes in the fair value of the award cumulatively adjusted through compensation expense each period. During the three and six months ended June 30, 2013 no compensation expense was recognized related to the C Shares as a change in control, liquidating event or initial public offering related to the Company (as defined in the MacDermid Holdings operating agreement) was not probable. The estimated fair value of the Class C Shares (all tranches) was approximately \$9,030 at June 30, 2013.

7. PENSION, POST-RETIREMENT AND POST-EMPLOYMENT PLANS

The components of net periodic pension and postretirement benefit costs for the Successor and Predecessor Quarterly and Six Month Periods are as follows:

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

| | For the three months ended June 30, | | | | For the six months ended June 30, | | | |
|---|-------------------------------------|---------|----------------------|----------|-----------------------------------|---------|----------------------|----------|
| | 2014 | | 2013 | | 2014 | | 2013 | |
| | <i>(Successor)</i> | | <i>(Predecessor)</i> | | <i>(Successor)</i> | | <i>(Predecessor)</i> | |
| Pension & SERP Benefits: | Domestic | Foreign | Domestic | Foreign | Domestic | Foreign | Domestic | Foreign |
| Net periodic cost (benefit): | | | | | | | | |
| Service cost | \$ - | \$ 211 | \$ 1,078 | \$ 174 | \$ - | \$ 419 | \$ 2,156 | \$ 348 |
| Interest cost on the projected benefit obligation | 1,728 | 768 | 1,565 | 768 | 3,456 | 1,523 | 3,130 | 1,536 |
| Expected return on plan assets | (2,433) | (913) | (2,005) | (1,283) | (4,866) | (1,811) | (4,010) | (2,566) |
| Amortization of prior service cost | - | - | 23 | - | - | - | 46 | - |
| Amortization of net loss | - | - | 505 | 135 | - | - | 1,010 | 270 |
| Net periodic (benefit) cost | \$ (705) | \$ 66 | \$ 1,166 | \$ (206) | \$ (1,410) | \$ 131 | \$ 2,332 | \$ (412) |

| | For the three months ended June 30, | | | | For the six months ended June 30, | | | |
|---|-------------------------------------|---------|----------------------|---------|-----------------------------------|---------|----------------------|---------|
| | 2014 | | 2013 | | 2014 | | 2013 | |
| | <i>(Successor)</i> | | <i>(Predecessor)</i> | | <i>(Successor)</i> | | <i>(Predecessor)</i> | |
| Postretirement Benefits: | Domestic | Foreign | Domestic | Foreign | Domestic | Foreign | Domestic | Foreign |
| Net periodic cost (benefit): | | | | | | | | |
| Service cost | \$ 14 | \$ 7 | \$ 18 | \$ 11 | \$ 28 | \$ 14 | \$ 36 | \$ 22 |
| Interest cost on the projected benefit obligation | 83 | 8 | 73 | 10 | 166 | 16 | 146 | 20 |
| Amortization of prior service cost | - | - | (35) | 7 | - | - | (70) | 14 |
| Net periodic cost | \$ 97 | \$ 15 | \$ 56 | \$ 28 | \$ 194 | \$ 30 | \$ 112 | \$ 56 |

No domestic pension service cost was recognized in the Successor Quarterly or Six month Periods, nor will be in future periods, as benefits in the domestic pension plan were frozen in connection with the MacDermid Acquisition.

8. DEBT

The Company's debt consisted of the following:

| | June 30, 2014 | December 31, 2013 |
|--|---------------|-------------------|
| Borrowings under lines of credit | \$ - | \$ - |
| First lien secured credit facility, due 2020, interest at the greater of 4.00% or LIBOR plus 3.00%, weighted average interest rate of 4.00% at June 30, 2014 | 747,450 | 751,225 |
| Other | 1,000 | 1,024 |
| Total debt | 748,450 | 752,249 |
| Less: current portion debt | (7,953) | (7,958) |
| Total long-term debt | \$ 740,497 | \$ 744,291 |

Predecessor Recapitalization and Refinancing

On April 12, 2007, the Predecessor closed three senior secured credit facilities consisting of (i) a \$360,000 tranche B term loan credit facility denominated in U.S. Dollars ("tranche B"), (ii) a \$250,000 tranche C term loan credit facility denominated in Euros ("tranche C") and (iii) a \$50,000 revolving credit facility denominated in U.S. Dollars.

On June 7, 2013, the Predecessor completed a refinancing arrangement whereby the outstanding tranche B term loan, tranche C term loan, revolving credit facility and senior subordinated notes payable were replaced with two new senior secured credit facilities (the "Refinancing"). These senior secured credit facilities consisted of (i) a \$805,000 first lien credit facility allocated between a \$755,000 term loan denominated in U.S. Dollars ("first lien term loan"), a \$25,000 revolving credit facility denominated in U.S. Dollars and \$25,000 multi-currency revolving credit facility and (ii) a \$360,000 second lien term loan credit facility denominated in U.S. Dollars ("second lien term loan"). The first lien term loan and related revolving credit facilities accrued interest at the greatest of 4.00% or LIBOR plus 3.00% and had quarterly principal payments of \$1,878. The revolving credit facility portion of the first lien term loan was scheduled to mature June 7, 2018. The first lien term loan was scheduled to mature June 7, 2020. The second lien term loan accrued interest at the greater of 7.75% or LIBOR plus 6.75% and was scheduled to mature on December 7, 2020. The first lien and second lien term loans were originally issued at discounts of \$1,887 and \$3,600, respectively. These senior secured credit facilities were guaranteed by MacDermid Holdings and certain of its direct and indirect wholly owned domestic subsidiaries and were secured by the personal property owned or hereafter acquired of MacDermid Holdings and certain of its direct and indirect wholly owned domestic subsidiaries and also 65% of the stock of MacDermid Holdings' first tier foreign subsidiaries, subject to customary exceptions, exclusions and release mechanisms.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

The recapitalization and refinancing transactions sources and uses of cash are summarized below:

Sources:

| | |
|-----------------------|---------------------|
| First lien term loan | \$ 755,000 |
| Second lien term loan | 360,000 |
| Cash | 117,080 |
| Total sources | <u>\$ 1,232,080</u> |

Uses:

| | |
|---|---------------------|
| Retire Tranche B and Tranche C term loans and accrued interest | \$ 345,426 |
| Retire senior subordinated notes, accrued interest and call premium | 368,164 |
| Redemption of Series A preferred stock and accumulated dividends | 500,000 |
| Fees and expenses | 13,003 |
| Discount on first lien term loan and second lien term loan | 5,487 |
| Total uses | <u>\$ 1,232,080</u> |

As part of the Refinancing, \$100,481 of the senior subordinated notes were called but not tendered on June 7, 2013 and were still outstanding on June 30, 2013. As a result, \$105,864 of the new debt proceeds from the refinance and recapitalization were escrowed to pay the outstanding called senior subordinated notes of \$100,481, redemption premium of \$3,182 and accrued interest \$2,201 through the tender date of July 8, 2013. The escrowed funds were paid to the holders of the remaining senior subordinated note holders on July 8, 2013.

MacDermid utilized \$500,000 of the proceeds from the new term loans to complete a recapitalization whereby the outstanding 9.00% cumulative Series A preferred shares and related accumulated payment in kind dividends were exchanged for cash and issuance of cumulative 9.50% cumulative Series B preferred shares. As a result, 44,977 shares of 9.50% cumulative Series B preferred stock were issued as part of the exchange, the 9.00% cumulative Series A preferred shares were retired and related accumulated payment in kind dividends were paid.

During the Predecessor Quarterly Period and in connection with the recapitalization and refinancing, MacDermid recorded a loss of \$18,788 on extinguishment of debt. This consisted of \$12,539 of called bond retirement premiums and \$6,249 of write-offs of deferred financing fees related to the extinguished debt.

In connection with the recapitalization and Refinancing, the Company recorded an additional \$13,003 of deferred financing costs during the Predecessor Quarterly Period, which were to be amortized into interest expense over seven years.

Successor Refinancing

In connection with the MacDermid Acquisition, on October 31, 2013, MacDermid amended its existing credit agreement dated as of June 7, 2013 (as amended, restated and/or otherwise modified on October 31, 2013 and from time to time, the "Amended and Restated Credit Agreement") and paid \$373,000, including \$13,000 in early termination fees and accrued and unpaid interest in connection with the repayment of the \$360,000 in principal on its second lien credit facility. Pursuant to the Amended and Restated Credit Agreement, Platform became a co-borrower on all obligations under the \$50,000 Revolving Credit Facility and the term loan (together, the "First Lien Facilities") and the negative and affirmative covenants contained therein were modified to reflect the new corporate structure; otherwise, the terms relating to the incremental facility, maturity, indicative margin, LIBOR floor, ranking, guarantors, mandatory prepayments and financial covenants remained unmodified by the amendment. In connection with the MacDermid Acquisition, the First Lien Credit Facilities were marked to fair value by adding the original discount of \$1,775 to the carrying value at the time as the fair value was approximately par.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

In connection with the Chemtura Acquisition as discussed in Note 2 – “Acquisitions of Businesses”, on April 16, 2014, Platform entered into a commitment letter (the “Debt Commitment Letter”) with Barclays Bank PLC for (i) \$600,000 of incremental first lien term loans (the “2014 First Lien Facility”) to be incurred under the Amended and Restated Credit Agreement and (ii) second lien term loans (the “2014 Second Lien Facility”) in an aggregate principal amount of \$120,000 for the purposes of financing the Chemtura Acquisition and the fees and expenses in connection therewith, on the terms and subject to the conditions set forth in the Debt Commitment Letter. On July 15, 2014, Platform entered into an amended and restated Debt Commitment Letter whereby the maximum commitment under the 2014 First Lien Facility was reduced to \$405,000 and the 2014 Second Lien Facility commitment was eliminated. These amendments resulted from Platform’s improved cash on hand position, primarily as a result of the Private Placement completed on May 21, 2014. Unless agreed otherwise, the First Lien Facility will mature on June 7, 2020 respectively.

During the Successor Quarterly Period, principal and interest payments of \$1,888 and \$7,577, respectively, were made on the first lien term loan. During the Successor Six Month Period, principal and interest payments of \$3,775 and \$15,089, respectively, were made on the first lien term loan. During the Predecessor Quarterly and Six Month Periods, interest payments of \$1,762 were made on the first lien term loan. During the Predecessor Quarterly and Six Month Periods, interest payments of \$1,628 were made on the second lien term loan.

The Company also has letters of credit outstanding of \$989 at June 30, 2014. As indicated above, letters of credit reduce the borrowings available under the Revolving Credit Facility.

Debt Covenants

The senior secured credit facilities contain various covenants including restrictions on liens, limitations on additional indebtedness, dividends and other distributions, entry into new lines of business, transactions with affiliates, use of loan proceeds, capital expenditures, restricted payments, amendments to organizational documents, accounting changes, sale and leaseback transactions and dispositions. In addition, the new revolving credit facilities requires the Company to comply with certain financial covenants, including a maximum consolidated leverage ratio, a minimum interest coverage ratio and limitations on capital expenditures if the Company’s funding under the revolving credit facility exceeds \$12,500 at the end of the fiscal quarter. As of June 30, 2014, the Company was in compliance with the debt covenants contained in the new senior secured credit facilities.

Other Debt Facilities

The Company carries various short-term debt facilities worldwide which are used to fund short-term cash needs. As of June 30, 2014 and December 31, 2013, there were no borrowings under these other debt facilities. The Company also has various overdraft facilities available. At June 30, 2014 and December 31, 2013, the capacity under these overdraft facilities was approximately \$23,028 and \$22,075, respectively. As of June 30, 2014, the Company’s overdraft lines bore interest rates ranging from 1% to 6.25%.

Predecessor Retired Senior Secured Credit Facility

In addition to scheduled repayments, the tranche B and tranche C loans contained mandatory prepayment provisions, whereby the Company was required to reduce the outstanding principal amounts of these loans based on excess cash flow (as defined in the credit agreement for the tranche B and tranche C loans) as of the most recent completed fiscal year. During the Predecessor Six Month Period, the Predecessor made a mandatory excess cash flow prepayment, based upon 2012 operating results, of \$10,277 on the tranche B term loan and \$6,810 on the tranche C term loan.

During the Predecessor Quarterly and Six Month Periods, the outstanding tranche B loan and tranche C loan were retired with payments of \$206,479 and \$138,737, respectively.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

During the Predecessor Quarterly Period, the Company recorded \$7,084 of other expense related to the remeasurement loss on the foreign currency denominated tranche C term loan. During the Predecessor Quarterly Period, the realized portion of the remeasurement gain on the foreign currency denominated tranche C term loan was approximately \$4,074.

During the Predecessor Six Month Period, the Company recorded \$3,261 of other expense related to the remeasurement loss on the foreign denominated tranche C term loan. During the Predecessor Six Month Period, the realized portion of the remeasurement gain on the foreign denominated tranche C term loan was approximately \$4,398.

Predecessor Retired Revolving Credit Facility

There were no balances outstanding under the revolving credit facility on the retirement date.

Predecessor Senior Subordinated Notes

As part of the Refinancing, the senior subordinated notes were called on June 7, 2013 and \$249,519 of principal and a redemption premium of \$9,357 were paid to retire the tendered senior subordinated notes. Additionally, \$105,864 of the new debt proceeds from the refinance and recapitalization were escrowed to pay the outstanding called senior subordinated notes of \$100,481. Additionally, proceeds from the refinancing were escrowed for a redemption premium of \$3,182 and accrued interest of \$2,201 related to these called senior subordinated notes. The escrowed funds were paid to the holders of the remaining senior subordinated note holders on July 8, 2013.

Japanese Senior Secured Bank Debt

In February 2007, the Predecessor borrowed approximately \$15,000 denominated in Japanese Yen in three separate notes that were paid in full by their respective maturity dates between 2009 and 2013. In September 2007, the Predecessor borrowed an additional \$2,519 denominated in Japanese Yen which was paid in full in July 2013. In October 2009, the Predecessor borrowed \$5,569 denominated in Japanese Yen which was paid in full in October 2013.

9. DERIVATIVE INSTRUMENTS

In the normal course of business, the Company is exposed to risks relating to changes in foreign currency exchange rates, interest rates and commodity prices. Derivative financial instruments, such as foreign currency exchange rate hedges are used to manage changes in market conditions related to foreign currency exchange rate volatility. All derivatives are recognized on the consolidated balance sheets at fair value at the end of each period. The counterparty to the Company's derivative agreements is a major international financial institution. The Company continually monitors its positions and the credit ratings of its counterparties, and does not anticipate nonperformance by the counterparties.

Foreign Currency

The Company conducts a significant portion of its business in currencies other than the U.S. Dollar, the currency in which the Company's consolidated financial statements are reported, and as a result, the Company's operating results are affected by foreign currency exchange rate volatility relative to the U.S. dollar. The Company's Autotype subsidiary in the United Kingdom uses the British Pound Sterling ("GBP") as its functional currency while approximately 25 percent of its revenues are denominated in U.S. Dollars. In order to protect against the risk of a strengthening GBP, the Company's corporate treasury group entered into forward contracts in 2013, on behalf of the Autotype subsidiary to deliver U.S. Dollars at a fixed GBP rate and to receive GBP in exchange for the U.S. Dollar. As of June 30, 2014, the aggregate U.S. Dollar notional amount of foreign currency forward contracts, designated as hedges, was \$0 as the hedge expired on that date. The Company uses the discounted period-end forward rates methodology to determine market value of its forward contracts.

During the Successor Quarterly Period, \$178 was recorded as unrealized gains to other comprehensive income related to foreign currency hedges. During the Successor Quarterly Period, the Company recorded a realized gain of \$315 in other income related to the settlement of hedged foreign exchange contracts.

During the Successor Six Month Period, \$163 was recorded as unrealized losses to other comprehensive income related to hedged foreign currency exchange contracts. During the Successor Six Month Period, the Company recorded realized gains of \$474 in other income related to the settlement of hedged foreign exchange contracts.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

During the Predecessor Quarterly Period, \$130 was recorded as unrealized gains to other comprehensive income related to foreign currency hedges. During the Predecessor Quarterly Period, the Company recorded realized (loss) of \$(111) in other expense related to the settlement of hedged foreign exchange contracts.

During the Predecessor Six Month Period, \$(650) was recorded as unrealized losses to other comprehensive income related to hedged foreign currency exchange contracts. During the Predecessor Six Month Period, the Company recorded realized (loss) of \$(334) in other expense related to the settlement of hedged foreign exchange contracts.

The following table summarizes the fair value of derivative instruments reported in the Condensed Consolidated Balance Sheets:

| Derivatives designated as hedging instruments: | Assets Balance Sheet Location | June 30, 2014 U.S. Dollar Amount | December 31, 2013 U.S. Dollar Amount |
|---|--------------------------------------|---|---|
| Foreign exchange contracts | Other current assets | \$ - | \$ 163 |
| Total derivative contracts | | \$ - | \$ 163 |

10. FAIR VALUE MEASUREMENTS

The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. The principal market is the market with the greatest level of activity and volume for the asset or liability. Absent a principal market to measure fair value, the Company has used the most advantageous market, which is the market in which the Company would receive the highest selling price for the asset or pay the lowest price to settle the liability, after considering transaction costs. However, when using the most advantageous market, transaction costs are only considered to determine which market is the most advantageous and these costs are then excluded when applying a fair value measurement.

Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.

The three levels of the fair value hierarchy are as follows:

- Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
- Level 2 – quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in non-active markets; and model derived valuations whose inputs are observable or whose significant valuation drivers are observable.
- Level 3 – significant inputs to the valuation model are unobservable and/or reflect the Company's market assumptions.

The following tables present the Company's financial instruments, assets and liabilities that are measured at fair value on a recurring basis:

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

| | June 30, 2014 | Fair Value Measurement Using | | |
|--------------------------------------|------------------|---|---|---|
| | | Quoted prices in active markets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) |
| Asset Category | | | | |
| Money market accounts | \$ 56,767 | \$ 56,767 | \$ - | \$ - |
| Available for sale equity securities | 2,315 | 1,507 | 808 | - |
| Total | <u>\$ 59,082</u> | <u>\$ 58,274</u> | <u>\$ 808</u> | <u>\$ -</u> |

| Liability Category | | | | |
|------------------------------------|-----------|------|------|-----------|
| Long term contingent consideration | \$ 58,600 | \$ - | \$ - | \$ 58,600 |

| | December 31, 2013 | Fair Value Measurement Using | | |
|--------------------------------------|-------------------|---|---|---|
| | | Quoted prices in active markets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) |
| Asset Category | | | | |
| Money market accounts | \$ 78,633 | \$ 78,633 | \$ - | \$ - |
| Available for sale equity securities | 2,302 | 1,470 | 832 | - |
| Derivatives | 163 | - | 163 | - |
| Total | <u>\$ 81,098</u> | <u>\$ 80,103</u> | <u>\$ 995</u> | <u>\$ -</u> |

| Liability Category | | | | |
|------------------------------------|-----------|------|------|-----------|
| Long term contingent consideration | \$ 34,800 | \$ - | \$ - | \$ 34,800 |

Money market accounts are included in cash and cash equivalents in the Condensed Consolidated Balance Sheets. Available for sale equity securities are included in other long term assets in the Condensed Consolidated Balance Sheets.

As discussed in Note 2 - "Acquisitions of Businesses", the long term contingent consideration represents a potential liability up to \$100,000 tied to achievement of EBITDA and stock trading price performance metrics over a seven year period in connection with the MacDermid Acquisition. The fair value of the long term contingent consideration was derived using the income approach with unobservable inputs, which included 1) future forecasts and present value assumptions for the EBITDA component and 2) the fair value of Common Stock and related volatility using a Monte Carlo simulation for the Share Price component and there was little or no market data associated with either component. The Company assessed the fair values of the liabilities as of date of the MacDermid Acquisition date and will assess quarterly thereafter until settlement in December 2020.

Nonrecurring Fair Value Measurements

The following table presents the carrying value and estimated fair value of the Company's first lien credit facility:

| | June 30, 2014 | | December 31, 2013 | |
|---|----------------|------------|-------------------|------------|
| | Carrying Value | Fair Value | Carrying Value | Fair Value |
| First lien credit facility, including current portion | \$ 747,450 | \$ 747,450 | \$ 751,225 | \$ 752,637 |

In accordance with the provisions of FASB ASC Topic 350, "Intangibles – Goodwill and Other" other intangible assets with carrying amounts of \$4,300 in the Graphic Solutions segment were written down to their implied fair values of \$3,900 using Level 3 inputs, resulting in intangible asset impairment charges of \$400. These impairment charges were included in selling, technical, general and administrative expense in the accompanying Condensed Consolidated Statements of Operations for the Predecessor Quarterly and Six Month Periods.

The following methods and assumptions were used to estimate the fair value of each class of the Company's financial instruments, assets and liabilities:

Money market accounts - The Company invests in various money market funds which are managed by financial institutions. These money market funds are not publicly traded, but historically have been highly liquid. The fair value of the money market accounts is determined by the banks based upon the funds' net asset values ("NAV"). All of the money market accounts currently permit daily investments and redemptions at \$1.00 NAV.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

Available for sale equity securities - Equity securities classified as available for sale are measured using quoted market prices at the reporting date multiplied by the quantity held. Level II equity securities are measured using quoted prices for similar instruments in active markets.

Derivatives - The fair values of foreign currency derivatives were determined using pricing models based upon observable market inputs including both forward and spot prices for the underlying currencies.

First Lien credit facility- The first lien credit facility is measured using quoted market prices at the reporting date multiplied by the carrying amount of the related debt. Such instruments are valued using Level 2 inputs.

11. STOCKHOLDERS' EQUITY

Successor

Amendment to Certificate of Incorporation

On June 12, 2014, the Company amended its Certificate of Incorporation to increase the number of authorized shares of the Company's Common Stock from two hundred million (200,000,000) to four hundred million (400,000,000) shares of Common Stock.

Founder Preferred Shares

On April 25, 2013, the Company issued one preferred share each to Mariposa Acquisition, LLC and Berggruen Acquisition Holdings, IV, Ltd, our founder entities (collectively, the "Founders"), for \$20.00. In connection with the initial public offering on May 22, 2013, the Founders purchased an additional 1,999,998 preferred shares ("Preferred" shares or stock; \$0.01 par value) for \$20,000. The preferred shares have certain voting rights. Beginning in 2014, the holders of the Preferred stock are entitled to receive a dividend in the form of shares of Common Stock equal to 20% of the appreciation of the market price of common shares multiplied by total initial offering shares (90,500,000 shares). In the first year a dividend is payable (if any), the dividend amount will be calculated at the calendar year-end based on the last ten trading days volume weighted average share price (the "Dividend Price) compared to the initial offering price of \$10.00 per ordinary share. In subsequent years, the dividend amount will be calculated based on the appreciated stock price compared to the highest Dividend Price previously used in calculating the Preferred stock dividends. Dividends are paid for the term the Preferred stock is outstanding. The Preferred shares may be converted into ordinary shares on a one for one basis (i) automatically in the event of a change of control of the Company following an acquisition, (ii) upon the last day of the seventh full financial year following the MacDermid Acquisition (December 31, 2020, (extendable by the Board of Directors for three additional years)), or (iii) at the option of the holder until December 31, 2020. No shares were issued or dividends paid in the Successor Quarterly or Six Month Period. Although not finally determinable until December 31, 2014, had the closing price for the Company's Common Stock on June 30, 2014 been used, a dividend of approximately 11.3 million shares would have been issued to the Founders.

Common Shares

In connection with the initial public offering on May 22, 2013, the Company issued 88,500,000 common shares (no par value) for gross proceeds of \$885,000. Also, on May 22, 2013, the Company issued an aggregate of 29,500 common shares to non-founder directors for \$10.00 per share. Each common share has voting rights and winding-up rights.

Each of the 2,000,000 Preferred shares, 88,500,000 common shares issued in connection with the initial public offering as well as the 29,500 common shares issued to the non-founder directors was issued with a warrant (90,529,500 warrants in aggregate), entitling the holder of each warrant to purchase one-third of common shares with a strike price of \$11.50 per common share. Each warrant was exercisable until three years from the date of an acquisition, unless mandatorily redeemed by the Company. The warrants were mandatorily redeemable by the Company at a price of \$0.01 should the average market price of a common share exceed \$18.00 for 10 consecutive trading days. In order to fund a portion of the cash consideration for the MacDermid Acquisition in November 2013, the Company conducted an offer to issue shares of Common Stock of the Company in exchange for \$10.50 and 3 warrants, up to a maximum of half of the warrants outstanding (the Warrant Exchange Offer") in which 40,386,840 warrants (representing \$141,354 in cash) were exercised and 13,462,280 underlying shares of Common Stock were issued. In conjunction with the Warrant Exchange Offer not being fully subscribed, on November 13, 2013, the Company issued 380,952 shares at \$10.50 per share to the Founders and issued 190,476 shares each to two of its independent directors at \$10.50 per share.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

In connection with the MacDermid Acquisition, the Company agreed to apply to list its shares on the NYSE and to change its jurisdiction of incorporation from the British Virgin Islands to Delaware, (the "Domestication"). The Company filed a registration statement on Form S-4 with the SEC to effect these changes. The registration statement was declared effective on January 22, 2014 and on that same date the Company completed its Domestication. On January 23, 2014, the Company's Common Stock began trading on the NYSE under the ticker symbol "PAH." On March 4, 2014, pursuant to the terms of an Exchange Agreement, dated October 25, 2013, between the Company and the fiduciaries of the MacDermid Savings Plan, the Company acquired the remaining approximately 3% of the MacDermid Plan Shares for approximately \$2,600 in cash (which is reflected in "Acquisition of business, net" in the accompanying Condensed Consolidated Statements of Cash Flows) and 1,670,386 shares of the Company's Common Stock.

In connection with the Domestication, (i) each ordinary share of the Company that was issued and outstanding immediately prior to the Domestication was automatically converted into one share of Common Stock (par value \$0.01) of the Company, (ii) outstanding options, warrants and other rights to acquire ordinary shares became options, warrants or rights to acquire the corresponding shares of Common Stock of the Company, and (iii) each Founder Preferred share that was issued and outstanding immediately prior to the Domestication was automatically converted into one share of Series A Preferred Stock of the Company.

On March 4, 2014, a mandatory redemption event occurred with respect to all of the Company's outstanding warrants. The Company fixed April 3, 2014 as the date of the mandatory redemption of the warrants, and accordingly, on or after that date, holders of warrants had no further rights with regard to such warrants except to receive \$0.01 per warrant. During the Successor Quarterly Period, 3,755,232 warrants were exercised for 1,251,744 shares of Common Stock resulting in proceeds to the Company of \$14,395. During the Successor Six Month Period, the Company issued 16,244,694 shares of Common Stock in connection with the exercise of a total of 48,734,082 warrants resulting in proceeds to the Company of \$186,814. On April 3, 2014, Platform completed the mandatory redemption of the remaining 8,580 outstanding warrants for \$0.01 per warrant.

On May 20, 2014, the Company issued to certain investors, an aggregate of 15,800,000 shares of the Company's Common Stock for an aggregate consideration of \$300,200, gross of transaction costs of approximately \$13,433, through the Private Placement. Such shares were not registered under the Securities Act of 1933, as amended (the "Securities Act") and were issued pursuant to an exemption from registration provided under Section 4(a)(2) of the Securities Act. On May 23, 2014, we filed a resale registration statement on Form S-1, which registered an aggregate of 14,825,000 shares of the Company's Common Stock acquired in the Private Placement. Such registration statement, as amended on June 13, 2014, was declared effective on June 19, 2014 and the 14,825,000 shares covered by such registration statement were eligible for resale in the public market immediately after the effective date of such registration statement.

Non-Controlling Interest

As described more fully in Note 2 – "Acquisitions of Businesses", in connection with the MacDermid Acquisition, certain sellers elected to receive shares of common stock of Platform's subsidiary PDH (the "PDH Common Stock") representing approximately \$97,500, which is classified as a non-controlling interest on the Condensed Consolidated Balance Sheets at June 30, 2014 and December 31, 2013 and will continue to be until such time as it is exchanged for Platform's Common Stock. Approximately \$1,314 and \$3,068 of net income has been allocated to the non-controlling interest for the three and six months ended June 30, 2014, respectively, and is included in the accompanying Condensed Consolidated Statements of Operations.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

A reconciliation of consolidated changes in equity for the Successor Six Month Period, the Platform Preacquisition Period and the Predecessor Six Month Period is as follows:

Successor

| | <u>Preferred Stock</u> | | <u>Common Stock</u> | | | Additional Paid-in Capital | Accumulated Deficit | Accumulated other comprehensive income (loss) | Total Stockholders' Equity | Non- controlling interest | Total equity |
|--|------------------------|--------------|---------------------|-----------------|---------------------|----------------------------------|------------------------|--|----------------------------------|---------------------------------|--------------|
| | Shares | Amount | Shares | Amount | Amount | | | | | | |
| Balance at December 31, 2013 | 2,000,000 | \$ - | 103,571,941 | \$ - | \$ 1,212,038 | \$ (194,222) | \$ 1,265 | \$ 1,019,081 | \$ 96,021 | \$ 1,115,102 | |
| Impact of Domestication | - | 20 | - | 1,016 | (1,036) | - | - | - | - | - | |
| Issuance of common shares @ \$11.00 per share on January 5, 2014 | - | - | 3,959 | - | 44 | - | - | 44 | - | 44 | |
| Exercise of warrants for common shares @ \$11.50 per share | - | - | 16,244,694 | 163 | 186,652 | - | - | 186,815 | - | 186,815 | |
| Issuance of common shares @\$19.00 per share in connection with Private Placement Offering | - | - | 15,800,000 | 158 | 300,042 | - | - | 300,200 | - | 300,200 | |
| Issuance costs in connection with Private Placement Offering | - | - | - | - | (13,433) | - | - | (13,433) | - | (13,433) | |
| Issuance of common shares @\$11.00 per share in connection with 401(k) Exchange Agreement | - | - | 1,670,386 | 16 | 18,358 | - | - | 18,374 | - | 18,374 | |
| Recovery of short swing profits, net | - | - | - | - | 515 | - | - | 515 | - | 515 | |
| Equity compensation expense | - | - | - | - | 303 | - | - | 303 | - | 303 | |
| Net (loss) income | - | - | - | - | - | (7,794) | - | (7,794) | 3,334 | (4,460) | |
| Foreign currency translation adjustments | - | - | - | - | - | - | 22,975 | 22,975 | 14 | 22,989 | |
| Pension and postretirement plans, tax benefit of \$11 | - | - | - | - | - | - | 228 | 228 | - | 228 | |
| Derivatives valuation, net of tax benefit of \$63 | - | - | - | - | - | - | (100) | (100) | - | (100) | |
| Unrealized gain on available for sale equity securities, net of tax provision of \$2 | - | - | - | - | - | - | 4 | 4 | - | 4 | |
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | (380) | (380) | |
| Balance at June 30, 2014 | <u>2,000,000</u> | <u>\$ 20</u> | <u>137,290,980</u> | <u>\$ 1,353</u> | <u>\$ 1,703,483</u> | <u>\$ (202,016)</u> | <u>\$ 24,372</u> | <u>\$ 1,527,212</u> | <u>\$ 98,989</u> | <u>\$ 1,626,201</u> | |

Successor

| | <u>Preferred Stock</u> | | <u>Common Stock</u> | | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Equity |
|---|------------------------|--------|---------------------|--------|----------------------------------|------------------------|----------------------------------|
| | Shares | Amount | Shares | Amount | | | |
| Balance at April 23, 2013 (Inception) | - | \$ - | - | \$ - | \$ - | \$ - | \$ - |
| Issuance of preferred shares @ \$10.00 per share on April 25, 2013 | 2 | - | - | - | - | - | - |
| Issuance of preferred shares @ \$10.00 per share with matching warrants on May 22, 2013 along with 2 matching warrants matching with previously issued preferred shares | 1,999,998 | - | - | - | 20,000 | - | 20,000 |
| Issuance of common shares @ \$10.00 per | | | | | | | |

| | | | | | | | |
|---|------------------|-------------|-------------------|-------------|-------------------|----------------|-------------------|
| share with matching warrants on May 22, 2013 | - | - | 88,529,500 | - | 885,296 | - | 885,296 |
| Equity offering cost | - | - | - | - | (24,078) | - | (24,078) |
| Equity compensation expense | - | - | - | - | 49 | - | 49 |
| Net loss | - | - | - | - | - | (80) | (80) |
| Balance at June 30, 2013 | <u>2,000,000</u> | <u>\$ -</u> | <u>88,529,500</u> | <u>\$ -</u> | <u>\$ 881,267</u> | <u>\$ (80)</u> | <u>\$ 881,187</u> |

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

Predecessor

| | Series A Preferred Shares | Series B Preferred Shares | Common Shares | Additional Paid-In Capital | Accumulated deficit | Accumulated other comprehensive income (loss) | Treasury Stock | Total Stockholders' Equity | Non- controlling interest | Total equity (deficit) |
|---|---------------------------------|---------------------------------|------------------|----------------------------------|------------------------|--|-------------------|----------------------------------|---------------------------------|------------------------------|
| Balance at December 31, 2012 | \$ 525,027 | \$ - | \$ 50,000 | \$ 2,318 | \$ (273,086) | \$ (30,270) | \$ (1,264) | \$ 272,725 | \$ (288) | \$ 272,437 |
| Net income | - | - | - | - | 9,393 | - | - | 9,393 | 180 | 9,573 |
| Equity compensation | - | - | - | 78 | - | - | - | 78 | - | 78 |
| Accrual of paid in kind dividend on cumulative preferred shares | 20,805 | 267 | - | - | (21,072) | - | - | - | - | - |
| Foreign currency translation adjustments | - | - | - | - | - | (22,009) | - | (22,009) | (32) | (22,041) |
| Derivatives valuation, net of tax benefit of \$227 | - | - | - | - | - | (423) | - | (423) | - | (423) |
| Unrealized loss on available for sale equity securities, net of tax expense of \$17 | - | - | - | - | - | 32 | - | 32 | - | 32 |
| Shares repurchased | (500,000) | - | - | - | - | - | (8) | (500,008) | - | (500,008) |
| Shares exchanged | (44,977) | 44,977 | - | - | - | - | - | - | - | - |
| Shares canceled | (855) | - | (417) | - | - | - | 1,272 | - | - | - |
| Dividend paid to non-controlling interest partner | - | - | - | - | - | - | - | - | (304) | (304) |
| Contribution from non-controlling interest | - | - | - | - | - | - | - | - | 17 | 17 |
| Balance at June 30, 2013 | \$ - | \$ 45,244 | \$ 49,583 | \$ 2,396 | \$ (284,765) | \$ (52,670) | \$ - | \$ (240,212) | \$ (427) | \$ (240,639) |

The income tax benefit (provision) allocated to the components of other comprehensive income for the Successor and Predecessor Quarterly and Six Month Periods is as follows:

| | For the three months ended June 30, | | For the six months ended June 30, | |
|--|-------------------------------------|-----------------------|-----------------------------------|-----------------------|
| | 2014 (Successor) | 2013 (Predecessor) | 2014 (Successor) | 2013 (Predecessor) |
| Foreign currency translation adjustment | \$ - | \$ - | \$ - | \$ - |
| Unrealized gain loss on available for sale securities | (20) | 33 | (2) | (17) |
| Pension and postretirement plans | - | - | 11 | - |
| Derivative valuation | 73 | (45) | 63 | 227 |
| Income tax benefit (provision) related to other comprehensive income | \$ 53 | \$ (12) | \$ 72 | \$ 210 |

12. EARNINGS PER SHARE

A computation of the weighted average shares outstanding for the Successor Quarterly and Six Month Periods and Platform Preacquisition Period follows.

| (in thousands) | Three months ended | Period from | Six months ended | Period from |
|--|--------------------|--|------------------|--|
| | June 30, 2014 | Inception (April 23, 2013) through June 30, 2013 | June 30, 2014 | Inception (April 23, 2013) through June 30, 2013 |
| Net income attributable to common shareholders | \$ (376) | \$ (80) | \$ (7,794) | \$ (80) |
| Basic weighted average common shares outstanding | 128,595 | 88,529 | 117,937 | 88,529 |
| Dilutive weighted average common shares outstanding ¹ | 128,595 | 88,529 | 117,937 | 88,529 |

¹ No share adjustments are included in the dilutive weighted average shares outstanding computation as each period was a net loss.

The following weighted-average stock options and warrants were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive (in thousands).

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

| | Three months ended June 30, 2014 | Six months ended June 30, 2014 |
|--|---|---|
| Number of shares contingently issuable for founder preferred share dividend rights | 11,279 | 11,279 |
| Number of shares issuable upon conversion of the PDH non-controlling interest | 8,775 | 8,775 |
| Number of shares issuable upon conversion of founder preferred shares | 2,000 | 2,000 |
| Number of shares contingently issuable for the contingent consideration | 713 | 713 |
| Number of warrants | - | 2,243 |
| Number of shares issuable upon conversion of the 401k exchange rights | - | 544 |
| Number of stock options | 88 | 80 |
| Number of restricted stock shares and units | 2 | 1 |
| | <u>22,857</u> | <u>25,635</u> |

13. CONTINGENCIES, ENVIRONMENTAL AND LEGAL MATTERS

Asset Retirement Obligations

The Company has recognized asset retirement obligations (“AROs”) for properties where it can make a reasonable estimate of the future expenditures necessary to satisfy the related obligations. The Company considers identified legally enforceable obligations, estimated settlement dates and appropriate discount and inflation rates in calculating the fair value of its AROs. At June 30, 2014 and December 31, 2013, the Company has accrued \$5,364 and \$4,765, respectively, for its AROs at sites in the U.S., Europe and Japan. The AROs are classified in the accompanying Condensed Consolidated Balance Sheets as of June 30, 2014 and December 31, 2013 as follows:

| | June 30, 2014 | December 31, 2013 |
|--|----------------------|--------------------------|
| Accrued expenses and other current liabilities | \$ 463 | \$ 69 |
| Other long-term liabilities | 4,901 | 4,696 |
| | <u>\$ 5,364</u> | <u>\$ 4,765</u> |

Environmental

The Company is a manufacturer and distributor of specialty chemical products, and is exposed to claims with respect to environmental cleanup or other matters, including those in connection with the disposal of hazardous materials. The Company is subject to extensive domestic and foreign laws and regulations relating to environmental protection and worker health and safety, including those governing discharges of pollutants into the air and water, the management and disposal of hazardous substances and wastes, and the cleanup of contaminated properties. The Company has incurred, and will continue to incur, costs and capital expenditures in complying with these laws and regulations. Additional costs could be incurred, including cleanup costs, fines, sanctions, and third-party claims, as a result of violations of or liabilities under environmental laws.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of potentially responsible parties. The Company has received notices of violation with respect to instances of non-compliance with environmental laws. A number of facilities and former facilities of the Company have been environmentally impacted from historic operations and some facilities are in the process of being investigated and remediated. As of June 30, 2014 and December 31, 2013, \$2,250 and \$2,896, respectively, was reserved for various environmental matters. Ultimate costs may vary from current estimates, and the discovery of additional contaminants at these facilities or other sites, or the imposition of additional cleanup obligations or third-party claims relating thereto could result in additional costs. Management believes that any possible losses related to environmental remediation in addition to the amounts recorded as of June 30, 2014 and December 31, 2013 would not be material to the Company’s consolidated financial position, results of operations or cash flows.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

Legal Proceedings

On July 8, 2014, a federal court jury found in favor of MacDermid Printing Solutions LLC ("MPS") in litigation against Cortron, Inc. ("Cortron") and awarded MPS \$3,941 in anti-trust damages; \$7,904 in breach of contract damages; \$3,791 and additional punitive damages for misappropriation of trade secrets, and \$11,875 plus additional punitive damages for unfair trade practices. The actual aggregate amount of damages, including the amount of punitive damages and an award of attorney fees will be determined by the presiding judge after post-trial briefing by the parties. Cortron may appeal the verdict; accordingly, MPS's ability to collect on the judgment is uncertain. All proceeds from this litigation are subject to the pending litigation provisions of the Platform Business Combination Agreement as discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

From time to time, the Company is involved in various legal proceedings in the normal course of its business. Management believes that the resolution of these claims, to the extent not covered by insurance, will not individually or in the aggregate, have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. As of June 30, 2014 and December 31, 2013, the Company has reserved approximately \$3,293 and \$2,881, respectively, for its outstanding legal proceedings.

14. INCOME TAXES

The tax impact of the year to date fair value adjustment to the long term contingent consideration liability was recorded in the interim periods as a reliable estimate of the full year adjustment could not be reasonably made. Additionally, unrecognized tax benefits of approximately \$7.6 million may be recognized within the next 12 months.

The Company has historically provided deferred taxes under ASC 740-30-25, formerly APB 23, for the presumed repatriation to the United States earnings from several non-U.S. subsidiaries. The indefinite reversal criterion of ASC 740-30-25 allows the Company to overcome that presumption to the extent the earnings are indefinitely reinvested outside the United States.

In June 2014, the Company determined that approximately \$23.7 million of certain foreign subsidiaries' undistributed net earnings would now be indefinitely reinvested in operations outside the United States. These earnings will provide the Company an opportunity to reinvest in the existing international business and provide funding for future acquisitions outside of the United States. As a result of the change in assertion, the Company reduced its deferred tax liabilities related to undistributed foreign earnings by \$4.5 million as a discrete item in the second quarter.

15. RELATED PARTY TRANSACTIONS

Immediately prior to the closing of the MacDermid Acquisition, each Retaining Holder, including certain officers of MacDermid, executed a RHTSA with the Company pursuant to which they agreed to exchange their respective interests in MacDermid Holdings for PDH Common Stock of Platform's subsidiary PDH, at an exchange rate of \$11.00 per share plus, with respect to the common, class A and class B unit equity interests of MacDermid Holdings held by the Retaining Holder (i) a proportionate share of a contingent interest in certain pending litigation, and (ii) a proportionate share of up to \$100 million of contingent purchase price payable upon the attainment of certain EBITDA and stock trading price performance metrics during the seven-year period following the closing of the MacDermid Acquisition as discussed further in Note 2 - "Acquisitions of Businesses". Immediately prior to the closing of the MacDermid Acquisition, members of MacDermid management and certain affiliates, including certain officers of MacDermid, contributed all or a portion of their MacDermid Holdings interests to Tartan Holdings, LLC, a newly-formed Delaware limited liability company ("Tartan"), and Tartan agreed to receive the PDH Common Stock in exchange for such MacDermid Holdings equity interests. The resulting noncontrolling interest percentage for the Retaining Holders was 6.76%.

Pursuant to an Advisory Services Agreement between the Company and Mariposa Capital, LLC, an affiliate of one of our Founders, ("Mariposa"), advisory fees paid to Mariposa, for the Successor Quarterly and Six Month Periods were \$500 and \$1,000, respectively.

On November 7, 2013, the Company entered into a registration rights agreement with Pershing Square Capital Management, L.P. ("Pershing Square"), the beneficial owner of approximately 24.3% of the Company's outstanding shares as of June 30, 2014. Those shares were acquired by Pershing Square in the initial public offering and the Warrant Exchange Offer. Pursuant to the agreement, for so long as any of the included funds managed by Pershing Square holds any Platform shares, the Company agreed to cooperate with such holders' reasonable requests to facilitate any proposed sale of shares by the requesting holder(s) in accordance with the provisions of Rule 144 or any successor rule ("Rule 144") promulgated under the Securities Act, including, without limitation, by complying with the current public information requirements of Rule 144 and providing opinions of counsel, to the extent required. Additionally, the Company agreed that promptly after becoming eligible to utilize a Form S-3 registration statement, the Company will file with the SEC a registration statement on Form S-3 registering (among other securities) the resale of the Company shares held by the holders and use its commercially reasonable efforts to have such registration statement declared effective as soon as practicable after its filing. The Company's obligations under the registration rights agreement shall terminate on the earlier of (i) the date on which all of a holder's shares have been sold, and (ii) the date on which all of a holder's shares may be sold pursuant to Rule 144 without volume or other restrictions.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

For the three and six months ended June 30, 2013, the Company paid management fees of \$102 and \$204, respectively, to Court Square Capital Partners II LP, a Predecessor investor.

For the three and six months ended June 30, 2013, the Company paid management fees to Weston Presidio, a Predecessor investor, of \$23 and \$47, respectively.

16. RESTRUCTURING ACTIVITIES

During both the three and six months ended June 30, 2014, the Company recorded \$404 of restructuring expense relating to the elimination of certain positions in both the Graphic Solutions and the Performance Materials segments. During the three and six months ended June 30, 2013, the Company recorded \$46 and \$1,652, respectively, of restructuring expense primarily relating to the elimination of certain positions in both the Graphic Solutions and the Performance Materials segments. As of June 30, 2014, the Company has accrued restructuring costs of \$1,325 that are anticipated to be paid out in the next twelve months.

Restructuring expense was as follows for the three and six month periods ended June 30, 2014 and 2013:

| | For the three months ended June 30, | | For the six months ended June 30, | |
|------------------------------|--|----------------------|--|----------------------|
| | 2014 | 2013 | 2014 | 2013 |
| | <i>(Successor)</i> | <i>(Predecessor)</i> | <i>(Successor)</i> | <i>(Predecessor)</i> |
| Severance and other benefits | \$ 404 | \$ 46 | \$ 404 | \$ 1,652 |
| Total restructuring expense | <u>\$ 404</u> | <u>\$ 46</u> | <u>\$ 404</u> | <u>\$ 1,652</u> |

The activity in the restructuring liabilities for the Successor and Predecessor Six Month Periods was as follows:

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

| <i>Successor</i> | Balance, December 31, 2013 | For the Successor Period | | | Balance, June 30, 2014 |
|-------------------------------|----------------------------------|--------------------------|------------------|-------------------------|------------------------------|
| | | Charges to Expense | Cash Payments | Non-cash Adjustments | |
| <u>Graphic Solutions:</u> | | | | | |
| Severance and other benefits | \$ 699 | \$ 179 | \$ (291) | \$ - | \$ 587 |
| Total Graphics Solutions | 699 | 179 | (291) | - | 587 |
| <u>Performance Materials:</u> | | | | | |
| Severance and other benefits | 1,330 | 225 | (741) | (76) | 738 |
| Total Performance Materials | 1,330 | 225 | (741) | (76) | 738 |
| Total restructuring liability | \$ 2,029 | \$ 404 | \$ (1,032) | \$ (76) | \$ 1,325 |

| <i>Predecessor</i> | Balance, December 31, 2012 | For the Predecessor Period | | | Balance, June 30, 2013 |
|-------------------------------|----------------------------------|----------------------------|------------------|-------------------------|------------------------------|
| | | Charges to Expense | Cash Payments | Non-cash Adjustments | |
| <u>Graphic Solutions:</u> | | | | | |
| Severance and other benefits | \$ - | \$ 1,508 | \$ (643) | \$ - | \$ 865 |
| Total Graphics Solutions | - | 1,508 | (643) | - | 865 |
| <u>Performance Materials:</u> | | | | | |
| Severance and other benefits | 632 | 144 | (112) | (9) | 655 |
| Total Performance Materials | 632 | 144 | (112) | (9) | 655 |
| Total restructuring liability | \$ 632 | \$ 1,652 | \$ (755) | \$ (9) | \$ 1,520 |

17. SEGMENT INFORMATION

The Company's operations are organized into two reportable segments: Performance Materials and Graphic Solutions.

The Performance Materials segment manufactures and markets dynamic chemistry solutions that are used in the electronics, automotive and oil and gas production and drilling industries. Its products include surface and coating materials and water-based hydraulic control fluids. In conjunction with the sale of these products, we provide extensive technical service and support to ensure superior performance of their application. Within the Performance Materials segment, the Company has two primary categories of products. Industrial products are materials used to improve the performance or look of a component of an industrial part or process. Electronic products are materials used to manufacture and improve the performance of circuit boards and similar electronic items.

The Graphic Solutions segment primarily produces and markets photopolymers through an extensive line of flexographic plates that are used in the commercial packaging and printing industries. The Company evaluates the performance of its segments based on net sales and operating profit. Operating profit for each segment includes net sales to third parties, related cost of sales and operating expenses directly attributable to the segment. Operating profit for each segment includes an allocation of corporate costs such as corporate salary and wages, equity compensation expense and legal costs.

The following table summarizes financial information regarding each reportable segment's results of operations for the periods presented:

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES
Notes to the Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(Unaudited)

| | For the three months ended June 30, | | For the six months ended June 30, | |
|-------------------------------|-------------------------------------|------------------------------|-----------------------------------|------------------------------|
| | 2014 <i>(Successor)</i> | 2013 <i>(Predecessor)</i> | 2014 <i>(Successor)</i> | 2013 <i>(Predecessor)</i> |
| Net Sales: | | | | |
| Performance Materials | \$ 147,129 | \$ 145,274 | \$ 290,240 | \$ 284,098 |
| Graphic Solutions | 42,003 | 44,718 | 82,618 | 88,026 |
| Consolidated net sales | <u>189,132</u> | <u>189,992</u> | <u>372,858</u> | <u>372,124</u> |
| Operating profit (loss): | | | | |
| Performance Materials | 16,641 | 27,115 | 25,480 | 48,563 |
| Graphic Solutions | (11,035) | 9,517 | (15,882) | 17,845 |
| Consolidated operating profit | <u>\$ 5,606</u> | <u>\$ 36,632</u> | <u>\$ 9,598</u> | <u>\$ 66,408</u> |

18. SUBSEQUENT EVENTS

On August 4, 2014, MacDermid Agricultural Solutions Holdings B.V., a limited liability company incorporated and organized under the laws of the Netherlands and a wholly-owned subsidiary of Platform, as the purchaser (the "Purchaser"), and Platform, as guarantor, entered into an agreement (the "Agreement") with a representative (the "Vendor") of Percival S.A., a *société anonyme* incorporated and organized under the laws of Belgium ("Percival"), pursuant to which the Purchaser agreed to acquire Percival, including Percival's agrochemical business that does business under the Agriphar trade name and which product portfolio includes a wide range of herbicide, fungicides and insecticides (the "Agriphar Acquisition"), for €300 million, consisting of €285 million in cash, subject to working capital and other adjustments, and a number of shares of Common Stock equal to the U.S. Dollar equivalent of €15 million (the "Shares").

The Vendor agreed not to transfer the Shares prior to January 2, 2018 without the prior written consent of the Purchaser; it being understood that (i) as of January 2, 2016, the Vendor may freely transfer a maximum of 1/3 of the Shares, and (ii) as of January 2, 2017, the Vendor may freely transfer a maximum of an additional 1/3 of the Shares, subject to the terms and provisions of a solvency letter described in the Agreement. Platform has agreed to guarantee to the Vendor the due and punctual performance and observance by the Purchaser of all its obligations under the Agreement.

The Agriphar Acquisition is expected to close no later than December 31, 2014, subject to the satisfaction or waiver of certain customary and other closing conditions.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Information

From time to time, Platform may make or publish forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect Platform's current views with respect to, among other things, future events and performance. These statements may discuss, among other things, our adjusted earnings per share, expected or estimated revenue, the outlook for Platform's markets and the demand for its products, estimated sales, segment earnings, net interest expense, income tax provision, restructuring and other charges, cash flows from operations, consistent profitable growth, free cash flow, future revenues and gross operating and adjusted EBITDA margin improvement requirement and expansion, organic net sales growth, bank debt covenants, the success of new product introductions, growth in costs and expenses, the impact of commodities and currencies and Platform's ability to manage its risk in these areas, and the impact of acquisitions, divestitures, restructuring and other unusual items, including Platform's ability to successfully complete as well as integrate and obtain the anticipated results and synergies from its consummated and future acquisitions. Platform generally identifies forward-looking statements by words such as "anticipate," "estimate," "expect," "intend," "project," "plan," "predict," "believe," "seek," "continue," "outlook," "may," "might," "will," "should," "can have," "likely" or the negative version of these words or comparable words. Forward-looking statements are based on beliefs and assumptions made by management using currently available information. These statements are only predictions and are not guarantees of future performance, actions or events. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying beliefs and assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Factors that can cause actual results to differ materially from those reflected in the forward-looking statements include, among others, those discussed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March 31, 2014, and elsewhere in this report. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties, and we urge you not to place undue reliance on any forward looking statements, which reflect management's analysis, judgment, belief or expectation only as of the date hereof. The Company expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Historical results are not necessarily indicative of the results expected for any future period. You are advised, however, to consult any further disclosures we make on related subjects in the Company's Form 10-K, 10-Q and 8-K reports to the SEC.

The following "Overview" section is a brief summary of the significant items addressed in Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"). Investors should read the relevant sections of this MD&A for a complete discussion of the items summarized below. Unless the context otherwise requires, all references in this section to "Platform", the "Company," "we", "us", "our", and "Successor" refer to Platform Specialty Products Corporation and its subsidiaries, collectively, for all periods subsequent to the MacDermid Acquisition (as defined below). All references in this quarterly report on Form 10-Q to our "Predecessor" refer to MacDermid, Incorporated, a Connecticut corporation ("MacDermid") and its subsidiaries for all periods prior to the MacDermid Acquisition (as defined below).

Overview

We were initially incorporated with limited liability under the laws of the British Virgin Islands on April 23, 2013 under the name Platform Acquisition Holdings Limited. We were created for the purpose of acquiring a target company or business with an anticipated enterprise value of between \$750 million and \$2.50 billion. We completed our initial public offering in the United Kingdom on May 22, 2013, raising approximately \$881 million net proceeds and were listed on the London Stock Exchange.

On October 31, 2013, we indirectly acquired substantially all of the equity of MacDermid Holdings, LLC ("MacDermid Holdings"), which, at the time, owned approximately 97% of MacDermid (the "MacDermid Acquisition"). As a result, we became a holding company for the MacDermid business. We acquired the remaining 3% of MacDermid (the "MacDermid Plan Shares") on March 4, 2014, pursuant to the terms of an Exchange Agreement, dated October 25, 2013, between us and the fiduciaries of the MacDermid, Incorporated Profit Sharing and Employee Savings Plan (the "MacDermid Savings Plan"). Concurrently with the closing of the MacDermid Acquisition, we changed our name to Platform Specialty Products Corporation. On January 22, 2014, we changed our jurisdiction of incorporation from the British Virgin Islands to Delaware (the "Domestication"), and on January 23, 2014, our shares of common stock, par value \$0.01 per share ("Common Stock"), began trading on the New York Stock Exchange ("NYSE") under the ticker symbol "PAH".

The total consideration for the MacDermid Acquisition and the Exchange Agreement was approximately \$1.80 billion (including the assumption of approximately \$756 million of indebtedness), plus (i) up to \$100 million of contingent consideration tied to achievement of EBITDA and stock trading price performance metrics over a seven-year period following the closing of the MacDermid Acquisition and (ii) an interest in certain MacDermid pending litigation. The consideration for the MacDermid Acquisition was paid in both equity interests and cash. Certain sellers elected to receive common stock in our wholly owned subsidiary Platform Delaware Holdings, Inc. ("PDH") representing approximately \$97.0 million of the total consideration. Holders of PDH common stock have the right to exchange such shares for shares of our Common Stock, on a one-for-one basis, at 25% per year, after the earlier of October 31, 2014 or a change of control of Platform.

We are a global producer of high technology specialty chemical products and provider of technical services. As our name “Platform Specialty Products Corporation” implies, we continually seek opportunities to act as an acquirer and consolidator of specialty chemical businesses on a global basis, particularly those meeting Platform’s “asset lite, high touch” philosophy, which involves dedicating extensive resources to research and development and highly technical, post-sale customer service, while limiting our investments in fixed assets and capital expenditures. To date, Platform has completed one acquisition, the MacDermid Acquisition, on October 31, 2013, and announced the Chemtura Acquisition on April 16, 2014, and the proposed acquisition of Percival S.A., (“Percival”) including Percival’s agrochemical business that does business under the Agriphar trade name on August 6, 2014, which are both expected to close in the fourth quarter of 2014, subject to customary closing conditions.

Currently, our business involves the manufacture of a broad range of specialty chemicals, which we create by blending raw materials, and the incorporation of these chemicals into multi-step technological processes. These specialty chemicals and processes together encompass the products we sell to our customers in the electronics, metal and plastic plating, graphic arts, and offshore oil production and drilling industries. We refer to our products as “dynamic chemistries” due to their delicate chemical compositions, which are frequently altered during customer use. Our dynamic chemistries are used in a wide variety of attractive niche markets and we believe that the majority of our operations hold strong positions in the product markets they serve.

We generate revenue through the manufacture and sale of our dynamic chemistries and by providing highly technical post-sale service to our customers through our extensive global network of specially trained service personnel. Our personnel work closely with our customers to ensure that the chemical composition and function of our dynamic chemistries are maintained as intended. As an example, a customer will engage us to manufacture and sell a product consisting of a process composed of eight successive chemical baths, each of which is made up of our specialty chemicals, in order to enhance the overall performance of that customer’s circuit boards. In addition to providing such product, a member of our professional service team would visit the customer’s manufacturing facilities on a regular basis post-sale to ensure that the process sold maintains the correct chemical balance and can be used effectively in the manner and for the purpose desired.

While our dynamic chemistries typically represent only a small portion of our customers’ costs, we believe that they are critical to our customers’ manufacturing processes and overall product performance. Further, operational risks and switching costs make it difficult for our customers to change suppliers and allow us to retain customers and maintain our market positions.

We report our business in two operating segments: a Performance Materials segment and a Graphic Solutions segment.

Performance Materials—Our Performance Materials segment manufactures and markets dynamic chemistry solutions that are used in the electronics, automotive and oil and gas production and drilling industries. We operate in the Americas, Asia and Europe. Our products include surface and coating materials and water-based hydraulic control fluids. In conjunction with the sale of these products, we provide extensive technical service and support to ensure superior performance of their application. The regional sales mix in this segment has shifted over the past several years from more industrialized nations towards emerging markets, such as Asia and South America. To better serve customers in these markets, we have developed state-of-the-art facilities in São Paulo and Paraná, Brazil and Suzhou, China. We have approximately 550 personnel and three manufacturing facilities in Asia and remain focused on further increasing our presence in the region.

Graphic Solutions—Our Graphic Solutions segment primarily produces and markets photopolymers through an extensive line of flexographic plates that are used in the commercial packaging and printing industries. We manufacture photopolymers used to produce printing plates for transferring images onto commercial packaging, including packaging for consumer food products, pet food bags, corrugated boxes, labels and beverage containers. In addition, we also produce photopolymer printing plates for the flexographic and letterpress newspaper and publications markets. Our products are used to improve print quality and printing productivity. Flexography is a printing process that utilizes flexible printing plates made of rubber or other flexible plastics. Photopolymers are molecules that change properties upon exposure to light. Our business mix in this segment is focused on high innovation, higher cash flow businesses by offering new products. We believe growth in this segment will be driven by consumer demand and advertising.

Both of our operating segments include significant foreign operations. There are certain risks associated with our foreign operations. See Part I, Item 1A Risk Factors – “*Our substantial international operations subject us to risks not faced by domestic competitors, including unfavorable political, regulatory, labor, tax and economic conditions in other countries that could adversely affect our business, financial condition and results of operations*” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

We sell our products into three geographic regions: the Americas, Asia and Europe. Because the Performance Materials segment utilizes shared facilities and administrative resources and offers products that are distinct from those within the Graphic Solutions segment, we make decisions about how to manage our operations by reference to each segment and not with respect to the underlying products or geographic regions that comprise each segment.

For financial information about our operating segments, see Note 17 - "Segment Information" to our Condensed Consolidated Financial Statements included herein.

The following is a discussion of our financial condition and results of operations during the three months ended June 30, 2014 (the "Successor Quarterly Period"), the six months ended June 30, 2014 (the "Successor Six Month Period"), the three months ended June 30, 2013 (the "Predecessor Quarterly Period") and the six months ended June 30, 2013 (the "Predecessor Six Month Period") and for Platform, prior to the completion of the MacDermid Acquisition, for the period from Inception (April 23, 2013) through June 30, 2013 (the "Platform Preacquisition Period"). We did not own MacDermid for the Predecessor Quarterly Period, Predecessor Six Month Period or Platform Preacquisition Period. Consequently, these results may not be indicative of the results that we would expect to recognize for future periods.

Three Months Ended June 30, 2014 versus the Three Months Ended June 30, 2013

Net Sales

Net sales of approximately \$189.1 million in the Successor Quarterly Period decreased by \$0.9 million, or 0.5%, compared to the Predecessor Quarterly Period. Net sales for the Successor Quarterly Period were favorably impacted by foreign currency translation of approximately \$2.5 million as compared to the Predecessor Quarterly Period. Net sales of new products, which represent opportunities to enter markets adjacent to those we currently serve, was \$22.4 million for the Successor Quarterly Period, compared to \$18.6 million for the Predecessor Quarterly Period. Net sales decreased primarily due to decreased sales in the Graphic Solutions segment as a result of lower demand for newspaper plating products. We not only periodically introduce new products to market, but also continuously modify our existing products, often at the request of, or in collaboration with, customers.

Net sales in the Performance Materials segment in the Successor Quarterly Period increased by \$1.8 million, or 1.2%, as compared to the Predecessor Quarterly Period. The increase in net sales is primarily attributable to strong demand for core industrial and film products in Europe during the Successor Quarterly Period. These increases were partially offset by a reduction in sales of offshore production control fluids as compared to the Predecessor Quarterly Period. Net sales in the Graphic Solutions segment decreased in the Successor Quarterly Period by \$2.7 million, or 6.1%, as compared to the Predecessor Quarterly Period. The decrease in net sales is primarily attributable to lower demand for newspaper plating products.

By region, net sales in the Americas, Asia and Europe in the Successor Quarterly Period were \$66.9 million, \$52.8 million and \$69.4 million, respectively. In the Predecessor Quarterly Period, net sales in the Americas, Asia and Europe were \$72.6 million, \$53.2 million and \$64.2 million, respectively. Sales volumes, including the favorable foreign currency impact, were lower in the Americas in the Successor Quarterly Period primarily from the Graphic Solutions segment and lower offshore sales volume as previously discussed which was partially offset by an increase in European sales mainly attributable to higher demand for our core industrial and film products.

Changes in the average selling prices of the Company's products did not have a material impact on net sales for the Successor Quarterly Period compared to the Predecessor Quarterly Period.

Cost of Sales

Cost of sales decreased \$1.0 million, or 1.1%, in the Successor Quarterly Period compared to the Predecessor Quarterly Period. The decrease primarily corresponds to lower sales volume. As a percentage of net sales, cost of sales for the Successor Quarterly Period was 48.9% as compared to 49.2% in the Predecessor Quarterly Period.

Gross Profit

Gross profit increased in the Successor Quarterly Period by \$0.1 million, or 0.2%, as compared to the Predecessor Quarterly Period and was favorably impacted by foreign currency translation of approximately \$1.0 million as compared to the Predecessor Quarterly Period. Our gross margin was 51.1% in the Successor Quarterly Period as compared to 50.8% for the Predecessor Quarterly Period with the increase primarily due to favorable changes in product mix.

Selling, Technical, General and Administrative Expense

Selling, technical, general and administrative expense increased in the Successor Quarterly Period by \$30.8 million, or 57.0%, as compared to the Predecessor Quarterly Period. The increase in selling, technical, general and administrative expense is primarily attributable to a fair value adjustment to the long-term contingent consideration liability of \$10.8 million, incremental amortization expense on newly valued intangible assets associated with the MacDermid Acquisition of approximately \$9.3 million and transaction costs primarily in connection with the Chemtura Acquisition of approximately \$10.1 million in the Successor Quarterly Period. Excluding these adjustments, selling, technical, general and administrative expense as a percentage of net sales was 28.8% in the Successor Quarterly Period and 28.5% in the Predecessor Quarterly Period.

Research and Development Expense

Research and development expense was relatively consistent in both the Successor and Predecessor Quarterly Periods and was 3.1% as a percentage of net sales in both periods.

Operating Profit (Loss)

Operating profit for the Performance Materials segment in the Successor Quarterly Period decreased by \$10.4 million, or 38.5%, as compared to the Predecessor Quarterly Period. The decrease in operating profit is primarily attributable to the increase in selling, technical, general and administrative expenses as described above of approximately \$17.2 million associated with the MacDermid and Chemtura Acquisitions. Excluding these incremental expenses operating profit in the Performance Materials segment would have increased by approximately \$6.8 million in the Successor Quarterly Period primarily due to increases from higher margins on electronics industry products sold in Asia and core industrial and film products sold in Europe.

Operating profit for the Graphic Solutions segment in the Successor Quarterly Period decreased by \$20.5 million, or 216.4%, as compared to the Predecessor Quarterly Period. The decrease in operating profit is primarily attributable to the increase in selling, technical, general and administrative expenses as described above of approximately \$15.3 million associated with the MacDermid and Chemtura Acquisitions. Excluding these incremental expenses operating profit in the Graphic Solutions segment would have decreased by approximately \$5.2 million in the Successor Quarterly Period primarily due to the lower sales volume of newspaper plating products in the Successor Quarterly Period.

Restructuring Expense

Restructuring expense in the Successor Quarterly Period was \$0.4 million and was primarily associated with severance charges related to the elimination of certain positions in both the Performance Materials and Graphic Solutions segments in the Americas. Restructuring charges in the Predecessor Quarterly Period were not material.

Interest Expense, net

Interest expense, net decreased in the Successor Quarterly Period by \$5.2 million, or 40.3%, as compared to the Predecessor Quarterly Period. The decrease in interest expense is primarily attributable to lower debt balances outstanding in the Successor Quarterly Period as compared to the Predecessor Quarterly Period.

Loss on Extinguishment of debt

In the Predecessor Quarterly Period, we recorded a loss of \$18.8 million related to the refinancing of tranche B and tranche C term loans and senior subordinated notes. This amount consisted of \$12.5 million of call premiums on the senior subordinated notes and \$6.3 million of write-offs of deferred financing fees related to the extinguished debt.

Other (Expense) Income, net

Other expense decreased by \$2.5 million in the Successor Quarterly Period as compared to the Predecessor Quarterly Period. The decrease was primarily due to a reduction of mark to market losses on foreign currency denominated debt of \$2.3 million as compared to the Predecessor Quarterly Period.

Income Tax

The income tax benefit was \$4.1 million for the Successor Quarterly Period compared to a tax expense of \$7.8 million for the Predecessor Quarterly Period. The primary drivers of the difference between the statutory rate of 35% and the Company's effective tax rate for the Successor and Predecessor Quarterly Periods of 158.23% and 388.75%, respectively is as follows. The tax benefit for the Successor Period was increased by (\$4.2) million for a change in assertion that certain foreign earnings will no longer be repatriated to the US and for the imposition of foreign taxes at different rates (\$3.8) million. The benefit was decreased for the full tax impact of the non-deductible portion of the fair value adjustment to the long term contingent liability of \$2.8 million and changes in tax reserves \$1 million. The tax expense in the Predecessor Quarterly Period was increased for non-deductible expenses related to the retirement of bonds \$6.6 million, changes in tax reserves \$0.9 million and decreased by (\$1.3) million for the imposition of foreign taxes at different rates. The tax impact of the year to date fair value adjustment to the long term contingent consideration liability was fully recorded in the interim period as reliable estimates of the full year adjustment could not be reasonably made.

Six Months Ended June 30, 2014 versus the Six Months Ended June 30, 2013

Net Sales

Net sales of approximately \$372.9 million in the Successor Six Month Period increased by \$0.7 million, or 0.2%, compared to the Predecessor Six Month Period. Net sales for the Successor Six Month Period were also favorably impacted by foreign currency translation of approximately \$2.3 million as compared to the Predecessor Six Month Period. The increase in Net Sales was primarily attributable to an increase in net sales of the Performance Materials segment due to strong demand for industrial and film products in Europe and higher sales of electronic products in Asia. We believe that net sales of new products, which represent opportunities to enter markets adjacent to those we currently serve, was \$43.7 million for the Successor Six Month Period, compared to \$36.4 million for the Predecessor Six Month Period.

Net sales in the Performance Materials segment in the Successor Six Month Period increased by \$6.1 million, or 2.1%, as compared to the Predecessor Six Month Period. The increase in net sales is primarily attributable to strong demand for core industrial and film products in Europe and higher sales of electronic products in Asia during the Successor Six Month Period. These increases were partially offset by lower sales of offshore fluids as compared to the Predecessor Six Month Period. Net sales in the Graphic Solutions segment decreased in the Successor Six Month Period by \$5.4 million, or 6.1%, as compared to the Predecessor Six Month Period. The decrease in net sales is primarily attributable to lower demand for newspaper plating products.

By region, net sales in the Americas, Asia and Europe in the Successor Six Month Period were \$132.6 million, \$102.7 million and \$137.6 million, respectively. In the Predecessor Six Month Period, net sales in the Americas, Asia and Europe were \$141.7 million, \$102.1 million and \$128.3 million, respectively. Sales volumes, including the favorable foreign currency impact, were lower in the Americas in the Successor Six Month Period primarily from the Graphic Solutions segment and lower offshore sales volume which was partially offset by an increase in European sales mainly attributable to higher demand for our core industrial and film products.

Changes in the average selling prices of the Company's products did not have a material impact on net sales for the Successor Six Month Period compared to the Predecessor Six Month Period.

Cost of Sales

Cost of sales increased \$9.7 million, or 5.3%, in the Successor Six Month Period compared to the Predecessor Six Month Period. The increase is primarily due to the \$12.0 million elimination of manufacturer's profit in inventory charged to cost of sales related to the purchase accounting fair value adjustments to inventory associated with the MacDermid Acquisition in the first three months of 2014. Excluding this charge, cost of sales as a percentage of net sales for the Successor Six Month Period was 48.3% as compared to 49.0% in the Predecessor Six Month Period.

Gross Profit

Gross profit decreased in the Successor Six Month Period by \$8.9 million, or 4.7%, as compared to the Predecessor Six Month Period. The decrease in gross profit is primarily attributable to the elimination of manufacturer's profit in inventory charged to cost of sales in connection with the MacDermid Acquisition as previously discussed. Excluding this charge, our gross margin was 51.7% in the Successor Six Month Period as compared to 51.0% for the Predecessor Six Month Period with the increase primarily due to favorable changes in product mix.

Selling, Technical, General and Administrative Expense

Selling, technical, general and administrative expense increased in the Successor Six Month Period by \$48.8 million, or 44.3%, as compared to the Predecessor Six Month Period. The increase in selling, technical, general and administrative expense is primarily attributable to a fair value adjustment to the long-term contingent consideration liability of \$23.8 million and incremental amortization expense on acquired intangible assets associated with the MacDermid Acquisition of approximately \$15.9 million. Additionally, we incurred transaction costs primarily in connection with the Chemtura Acquisition of approximately \$10.1 million in the Successor Six Month Period. Excluding these adjustments, selling, technical, general and administrative expense as a percentage of net sales was 29.2% and 29.6% in the Successor and Predecessor Six Month Periods, respectively.

Research and Development Expense

Research and development expense increased by \$0.3 million in the Successor Six Month Period as compared to the Predecessor Six Month Period and was 3.2% as a percentage of net sales in both periods.

Operating Profit

Operating profit for the Performance Materials segment in the Successor Six Month Period decreased by \$23.0 million, or 47.5%, as compared to the Predecessor Six Month Period. The decrease in operating profit is primarily attributable to the increase in selling, technical, general and administrative expenses as described above of approximately \$33.1 million associated with the MacDermid and Chemtura Acquisitions. Excluding these incremental expenses operating profit in the Performance Materials segment would have increased by approximately \$10.1 million in the Successor Six Month Period primarily due to increases from higher margins on electronics industry products sold in Asia and core industrial and film products sold in Europe.

Operating profit for the Graphic Solutions segment in the Successor Six Month Period decreased by \$33.7 million, or 189.2%, as compared to the Predecessor Six Month Period. The decrease in operating profit is primarily attributable to the increase in selling, technical, general and administrative expenses as described above of approximately \$31.3 million associated with the MacDermid and Chemtura Acquisitions. Excluding these incremental expenses operating profit in the Graphic Solutions segment would have decreased by approximately \$2.4 million in the Successor Six Month Period primarily due to the lower sales volume of newspaper plating products in the Successor Six Month Period.

Restructuring Expense

Restructuring expense in the Successor Six Month Period was \$0.4 million and was primarily associated with severance charges related to the elimination of certain positions in both the Performance Materials and Graphic Solutions segments in the Americas. Restructuring expense in the Predecessor Six Month Period was approximately \$1.7 million and was primarily associated with restructuring charges related to the elimination of certain positions in the Graphic Solutions segment in the Americas.

Interest Expense, net

Interest expense, net decreased in the Successor Six Month Period by \$9.1 million, or 37.3%, as compared to the Predecessor Six Month Period. The decrease in interest expense is primarily attributable to lower debt balances outstanding in the Successor Six Month Period as compared to the Predecessor Six Month Period.

Loss on Extinguishment of debt

In the Predecessor Six Month Period, we recorded a loss of \$18.8 million related to the refinancing of tranche B and tranche C term loans and senior subordinated notes. This amount consisted of \$12.5 million of call premiums on the senior subordinated notes and \$6.3 million of write-offs of deferred financing fees related to the extinguished debt.

Other (Expense) Income, net

Other income decreased by \$1.2 million in the Successor Six Month Period as compared to the Predecessor Six Month Period primarily due to a reduction of mark to market gains on foreign currency denominated debt.

Income Tax

The income tax benefit was \$2.0 million for the Successor Six Month Period compared to a tax expense of \$14.1 million for the Predecessor Six Month Period. The primary drivers of the difference between the statutory rate of 35% and the Company's effective tax rate for the Successor and Predecessor Six Month Periods of 30.51% and 59.51%, respectively is as follows. The tax benefit for the Successor Six Month Period increased for the imposition of foreign taxes at different rates (\$4.5) million, and (\$4.5) million for a change in assertion that certain foreign earnings will no longer be repatriated to the U.S. and decreased for the full tax impact of the non-deductible portion of the fair value adjustment for the long term contingent liability of \$6.2 million and changes in reserves \$1.8 million. The tax expense in the Predecessor Six Month was increased for non-deductible expenses related to the retirement of bonds \$6.6 million and decreased for the imposition of foreign taxes at different rates of (\$2.4) million. The tax impact of the year to date fair value adjustment to the long term contingent consideration liability was fully recorded in the interim period as reliable estimates of the full year adjustment could not be reasonably made.

Liquidity and Capital Resources

Our primary sources of liquidity in the Successor Six Month Period were cash raised from the Private Placement, the Warrant Exchange Offer and cash generated from operations. Our primary uses of cash and cash equivalents are raw material purchases, salary expense, acquisitions, capital expenditures and debt service obligations. We believe that our cash and cash equivalent balance and cash generated from operations will be sufficient to meet our working capital needs, capital expenditures and other business requirements for at least the next twelve months. At June 30, 2014, we had \$643 million in cash and cash equivalents in addition to an unused line of credit of approximately \$49 million.

Of our \$643 million of cash and cash equivalents at June 30, 2014, \$68.2 million was held by our foreign subsidiaries. The majority of the cash held by foreign subsidiaries is generally available for the ongoing needs of our operations. The laws of certain countries may limit our ability to utilize cash resources held in those countries for operations in other countries. However, these laws are not likely to materially impact our liquidity. The operations of each foreign subsidiary generally fund such subsidiary's capital requirements. In the event that other foreign operations or operations within the United States require additional cash, we may transfer cash between and among subsidiaries as needed so long as such transfers are in accordance with law. As of June 30, 2014, we had the ability to repatriate \$17.2 million of cash at our discretion from the foreign subsidiaries and branches while the remaining balance of \$51.0 million was held at subsidiaries in which earnings are considered permanently reinvested. Repatriation of some of these funds could be subject to delay and could have potential tax consequences, principally with respect to withholding taxes paid in foreign jurisdictions. If cash is repatriated from jurisdictions in which earnings are considered permanently reinvested we will be required to accrue and pay U.S. income taxes on such repatriations. Additionally, the Company deposited \$315 million into an escrow account on July 3, 2014, which is restricted to the financing of the Chemtura Acquisition.

On May 20, 2014, we issued and sold to certain investors, all of whom qualify as "accredited investors" (as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended (the "Securities Act")), an aggregate of 15,800,000 shares of our Common Stock for an aggregate consideration of \$300.2 million, gross of transaction costs of approximately \$13.4 million, through the Private Placement. Such shares were not registered under the Securities Act and were issued pursuant to an exemption from the registration provided under Section 4(a)(2) of the Securities Act. On May 23, 2014, we filed a resale registration statement on Form S-1, which registered an aggregate of 14,825,000 shares of our Common Stock acquired in the Private Placement. Such registration statement, as amended on June 13, 2014, was declared effective on June 19, 2014 and the 14,825,000 shares covered by such registration statement were eligible for resale in the public market immediately after the effective date of such registration statement.

The following is a summary of our cash flows provided by (used in) operating, investing and financing activities during the periods indicated (\$ in thousands):

| <i>(amounts in thousands)</i> | For the six months ended June 30, 2014 | Period from Inception (April 23, 2013) through June 30, 2013 | For the six months ended June 30, 2013 |
|--|---|---|---|
| | <i>Successor</i> | <i>Successor</i> | <i>Predecessor</i> |
| Cash and cash equivalents, beginning of the period | \$ 123,040 | \$ - | \$ 143,351 |
| Cash provided by (used in) operating activities | 49,214 | (55) | 37,247 |
| Cash provided by (used in) investing activities | 240 | (359,933) | (2,630) |
| Cash provided by (used in) financing activities | 469,966 | 881,218 | (133,605) |
| Exchange rate impact on cash and cash equivalents | 300 | - | (1,455) |
| Cash and cash equivalents, end of the period | <u>\$ 642,760</u> | <u>\$ 521,230</u> | <u>\$ 42,908</u> |

Operating Activities

During the Successor Six Month Period, we generated \$49.2 million in cash from operating activities primarily due to a net loss of \$4.4 million offset by non-cash charge add-backs for depreciation and amortization of \$38.3 million, a fair value adjustment to the long-term contingent consideration liability of \$23.8 million and the elimination of the final portion of the manufacturer's profit in inventory in connection with the MacDermid Acquisition of \$12.0 million. These favorable changes were partially offset by a non-cash deferred tax benefit of \$13.8 million, lower accrued expenses of \$5.4 million primarily from payments of deferred compensation made during the Successor Six Month Period in addition to higher accounts receivable of \$2.0 million due to timing of sales as compared to the Predecessor Six Month Period.

During the Predecessor Six Month Period, we generated \$37.2 million in cash from operating activities primarily due to net income of \$9.6 million, non-cash charges for depreciation and amortization of \$19.7 million and loss on extinguishment of debt of \$18.8 million. These increases were partially offset by unfavorable changes in accounts receivable of \$10.6 million mainly from slower collections and accrued expenses of \$3.4 million primarily from higher interest payments made in the Predecessor Six Month Period.

The Company's management uses days sales outstanding ("DSO") to measure how efficiently it manages the billing and collection of accounts receivable. We calculate DSO by dividing the product of 360 and its accounts receivable balance by its annualized net sales. At June 30, 2014 and December 31, 2013, DSO was 68 days and 73 days, respectively.

The Company's management uses days in inventory ("DII") to calculate its efficiency at realizing inventories, which is calculated by dividing the product of 360 and its inventory balance, net of reserves, by its annualized cost of sales, excluding any intercompany sales. At June 30, 2014 and December 31, 2013, DII was 78 days and 88 days (inclusive of finished goods step-up adjustment of \$35.9 million and related recognition of two-thirds of the inventory step-up in the November and December 2013 of \$23.9 million in connection with the MacDermid Acquisition), respectively. Our products generally have shelf lives that exceed one year.

Investing Activities

During the Successor Six Month Period, we generated cash from investing activities of approximately \$0.2 million primarily from cash received for the working capital adjustment of \$8.5 million in connection with the MacDermid Acquisition partially offset by cash payments made in connection with the 401(k) exchange settlement of \$2.6 million and capital expenditures of \$4.6 million.

During the Platform Preacquisition Period, we used cash from investing activities of approximately \$359.9 million to purchase marketable securities.

During the Predecessor Six Month Period, we used cash from investing activities of approximately \$2.6 million primarily for capital expenditures.

Financing Activities

During the Successor Six Month Period, we generated cash from financing activities of \$470.0 million primarily from proceeds received from the issuance of common shares from the Private Placement, net of transaction costs, and warrant exercises of approximately \$473.6 million. These were partially offset by debt repayments of \$3.8 million.

During the Platform Preacquisition Period, we generated cash from financing activities of approximately \$881.2 million primarily from proceeds received from issuances of common and preferred shares.

During the Predecessor Six Month Period, we used cash from financing activities of \$133.6 million primarily for the repayment of long-term borrowings, including escrowed funds, of \$730.3 million, in addition to the payment of debt financing fees of \$12.6 million. We also repurchased Predecessor Series A Preferred Stock and accumulated dividends of \$500.0 million. Partially offsetting these uses were proceeds received from the issuance of debt in connection with a refinancing and recapitalization of \$1.11 billion. Refer to Note 8 – “Debt” for further discussion pertaining to these financing activities.

Financial Borrowings

Credit Facilities

We are party to an amended and restated credit agreement dated as of June 7, 2013 (as amended, restated and/or otherwise modified on October 31, 2013 and from time to time, the “Amended and Restated Credit Agreement”) consisting of (i) a \$755 million first lien credit facility (which we refer to as our “first lien credit facility”) and (ii) a \$50.0 million revolving credit facility (which we refer to as our “revolving credit facility”, and together with our first lien credit facility, our “credit facilities”). A portion of our revolving credit facility not in excess of \$15.0 million is available for the issuance of letters of credit. As of June 30, 2014, we had approximately \$747 million of indebtedness outstanding under our first lien credit facility and there were no borrowings under our revolving credit facility, other than stand-by letters of credit issued in the amount of \$1.0 million which reduce the borrowings available under our revolving credit facility. Our credit facilities contain various covenants, including limitations on additional indebtedness, dividends and other distributions, entry into new lines of business, use of loan proceeds, capital expenditures, restricted payments, restrictions on liens, transactions with affiliates, amendments to organizational documents, accounting changes, sale and leaseback transactions and dispositions. In addition, the revolving credit facility requires us to comply with certain financial covenants, including consolidated leverage and interest coverage ratios and limitations on capital expenditures if funding under the revolving credit facility exceeds \$12.5 million at the end of any fiscal quarter. As of June 30, 2014, the Company was in compliance with the debt covenants contained in our credit facilities.

In connection with the Chemtura Acquisition as discussed in Note 2 – “Acquisitions of Businesses,” on April 16, 2014, Platform entered into a commitment letter (the “Debt Commitment Letter”) with Barclays Bank PLC for (i) \$600 million of incremental first lien term loans (the “First Lien Facility”) to be incurred under the Amended and Restated Credit Agreement and (ii) second lien term loans (the “Second Lien Facility”) in an aggregate principal amount of \$120 million for the purposes of financing the Chemtura Acquisition and the fees and expenses in connection therewith, on the terms and subject to the conditions set forth in the Debt Commitment Letter. On July 15, 2014, Platform entered into an amended and restated Debt Commitment Letter whereby the maximum commitment under the First Lien Facility was reduced to \$405 million and the Second Lien Facility commitment was eliminated. These amendments resulted from Platform’s improved cash on hand position, primarily as a result of the Private Placement completed on May 21, 2014. Unless agreed otherwise, the First Lien Facility will mature on June 7, 2020.

Off-Balance Sheet Transactions

We use customary off-balance sheet arrangements, such as operating leases and letters of credit, to finance our business. None of these arrangements has or is reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The quantitative and qualitative disclosures about market risk required by this item have not changed materially from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March 31, 2014. For a discussion of our exposure to market risk, refer to Part II, Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” contained in our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March 31, 2014.

Item 4. Controls and Procedures

Our management, with the participation of our Chief Executive Officer, who is our principal executive officer, and Chief Financial Officer, who is our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

In the ordinary course of our business, we are subject to periodic lawsuits, investigations and claims, including, but not limited to, product liability claims, contractual disputes, premises claims and employment and environmental, health, and safety matters. Although we cannot predict with certainty the ultimate resolution of lawsuits, investigations and claims asserted against us, we do not believe any currently pending legal proceeding to which we are a party will have a material adverse effect on our business, prospects, financial condition, cash flows and results of operations.

We are a manufacturer and distributor of specialty chemical products, and are therefore exposed to the risk of liability or claims with respect to environmental cleanup or other matters, including those in connection with the disposal or releases of hazardous materials. We have received notices of violation with respect to instances of non-compliance with environmental laws. A number of our facilities and former facilities have been environmentally impacted from historic operations and some of our facilities are in the process of being investigated and remediated. See Note 13 to our condensed consolidated financial statements included herein.

We or our affiliates have been named as a potentially responsible party in numerous superfund sites due to historic operations. Asbestos and other hazardous substances are or may be present at our facilities. We are subject to extensive domestic and foreign laws and regulations relating to environmental protection and worker health and safety, including those governing discharges of pollutants into soil, air and water, the management and disposal of hazardous substances and wastes, and the cleanup of contaminated properties. We have incurred, and will continue to incur, costs and capital expenditures in complying with these laws and regulations. Additional costs could be incurred, including cleanup costs, fines, sanctions, and third-party claims, as a result of violations of or liabilities under environmental laws. As of June 30, 2014, the Company has reserved approximately \$3,293,000 for its outstanding legal proceedings.

Item 1A. Risk Factors

Except as set forth below, there have been no material changes to the Risk Factors described in Part I "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the SEC on March 31, 2014.

Risks Related to the Proposed Chemtura AgroSolutions Acquisition

There can be no assurance that the Chemtura AgroSolutions Acquisition will be completed.

On April 16, 2014, we signed a Stock and Asset Purchase Agreement with Chemtura, pursuant to which we agreed to the Chemtura Acquisition. We expect the Chemtura Acquisition to close in the fourth quarter of 2014, subject to customary closing conditions. There can be no assurance that the acquisition will be completed.

There are a number of risks and uncertainties relating to the Chemtura Acquisition. For example, the Chemtura Acquisition may not be completed, or may not be completed in the time frame, on the terms or in the manner currently anticipated, as a result of a number of factors, including, among other things, the failure of one or more of the conditions to closing. There can be no assurance that the conditions to closing of the Chemtura Acquisition will be satisfied or waived or that other events will not intervene to delay or result in the failure to close the Chemtura Acquisition. The Stock and Asset Purchase Agreement between us and Chemtura may be terminated by the parties thereto under certain circumstances, including, without limitation, if the Chemtura Acquisition has not been completed by November 1, 2014. Any delay in closing or a failure to close could have a negative impact on our business and the trading price of our Common Stock. In addition, if we fail to consummate the closing of the Chemtura Acquisition within one business day following the date the closing was required to be consummated pursuant to the terms of the Stock and Asset Purchase Agreement, solely as a result of the failure of our anticipated debt financing to be consummated (other than if such failure is a result of our breach of the Stock and Asset Purchase Agreement or the debt commitment letter we obtained in connection with the Stock and Asset Purchase Agreement), we will be obligated to pay Chemtura a cash termination fee of \$49.7 million.

The due diligence undertaken in connection with the Chemtura Acquisition may not have revealed all relevant considerations or liabilities of the Chemtura Agrosolutions business ("CAS"), which could have a material adverse effect on our financial condition or results of operations.

There can be no assurance that the due diligence undertaken by us in connection with the Chemtura Acquisition has revealed all relevant facts that may be necessary to evaluate such acquisition. Furthermore, the information provided during due diligence may have been incomplete, inadequate or inaccurate. As part of the due diligence process, we have also made subjective judgments regarding the results of operations, financial condition and prospects of CAS. If the due diligence investigation has failed to correctly identify material issues and liabilities that may be present in CAS, or if we consider any identified material risks to be commercially acceptable relative to the opportunity, we may incur substantial impairment charges or other losses following the Chemtura Acquisition. In addition, we may be subject to significant, previously undisclosed liabilities of CAS that were not identified during due diligence and which could contribute to poor operational performance and have a material adverse effect on our financial condition or results of operations.

We may fail to realize the growth prospects and other benefits anticipated from the Chemtura Acquisition.

The success of the Chemtura Acquisition will depend, in part, on our ability to realize the anticipated business opportunities and growth prospects from the Chemtura Acquisition. We may never realize these business opportunities and growth prospects. The Chemtura Acquisition and related integration will require significant efforts and expenditures. Our management might have its attention diverted while trying to integrate operations and corporate and administrative infrastructures and the cost of integration may exceed our expectations. We may also be required to make unanticipated capital expenditures or investments in order to maintain, improve or sustain the acquired operations or take writeoffs or impairment charges and may be subject to unanticipated or unknown liabilities relating to the Chemtura Acquisition. If any of these factors limit our ability to complete the Chemtura Acquisition and integration of operations successfully or on a timely basis, our expectations of future results of operations following the Chemtura Acquisition might not be met.

In addition, it is possible that the integration process could result in the loss of key employees, the disruption of ongoing businesses, tax costs or inefficiencies, or inconsistencies in standards, controls, information technology systems, procedures and policies, any of which could adversely affect our ability to achieve the anticipated benefits of the Chemtura Acquisition and could harm our financial performance.

Our and CAS' business relationships, including customer relationships, may be subject to disruption due to uncertainty associated with the Chemtura Acquisition.

Parties with which we or CAS do business may experience uncertainty associated with the Chemtura Acquisition, including with respect to current or future business relationships with us, CAS or the combined business. These business relationships may be subject to disruption as customers and others may attempt to negotiate changes in existing business relationships or consider entering into business relationships with parties other than us, CAS or the combined business, including our competitors or those of CAS. These disruptions could have a material adverse effect on the sales, operating results and financial condition of the combined business. The adverse effect of such disruptions could be exacerbated by a delay in the completion of the Chemtura Acquisition or termination of the stock and asset purchase agreement between us and Chemtura.

Risks Relating to Ownership of our Common Stock

Volatility of our stock price could adversely affect our stockholders.

The market price of our Common Stock could fluctuate significantly as a result of:

- quarterly variations in our operating results;
- interest rate changes;
- changes in the market's expectations about our operating results;

- our operating results failing to meet the expectation of securities analysts or investors in a particular period;
- changes in financial estimates and recommendations by securities analysts concerning our Company or our industry in general;
- operating and stock price performance of other companies that investors deem comparable to us;
- news reports relating to trends in our markets;
- changes in laws and regulations affecting our business;
- material announcements by us or our competitors;
- sales of substantial amounts of Common Stock by our directors, executive officers or significant stockholders or the perception that such sales could occur;
- general economic and political conditions such as recessions and acts of war or terrorism; and
- the risk factors set forth in our public filings and other matters discussed therein.

Fluctuations in the price of our Common Stock could contribute to the loss of all or part of a stockholder's investment in our Company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Previously Disclosed

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

Appointment of Certain Officers

On May 3, 2014, the Board voted to appoint Michael V. Kennedy, age 53, as Vice President of Tax and Treasurer of Platform, effective immediately. On August 5, 2014, the Board decided that, in his role as Vice President of Tax and Treasurer, Mr. Kennedy would be an executive officer for reporting purposes under Section 16(a) of the Exchange Act. Mr. Kennedy had been Vice President of Tax of MacDermid since December 2013. Mr. Kennedy has also served as the Treasurer and Director of Tax of MacDermid Group, Inc. since its formation and as the Director of Tax of MacDermid, continuously since August 2006 and previously from January 1997 until September 2001. Mr. Kennedy has also served as Treasurer of MacDermid, since May 2011. From October 2001 through June 2006, Mr. Kennedy was Vice President-Tax for Allied Domecq North American Corporation, an alcoholic beverage company. From October 1989 to December 1996, he was a tax manager at Dynamics Corporation of America, an electrical appliance and electronic device manufacturer. Mr. Kennedy began his career at Arthur Andersen & Co as a tax accountant and a senior tax supervisor from 1986 to 1989. Mr. Kennedy is a certified public accountant and received a Bachelor of Business Administration in Accounting from Pace University.

On August 5, 2014, the Board also voted to appoint John L. Cordani, age 51, as Vice President – Legal and Secretary of Platform, effective immediately. In his new role as Vice President - Legal and Secretary, Mr. Cordani will be an executive officer for reporting purposes under Section 16(a) of the Exchange Act. Mr. Cordani's biographical information can be found in the Company's definitive proxy statement filed with the SEC on April 25, 2014.

Finally, on August 5, 2014, the Board voted to appoint Robert L. Worshek, age 43, as Vice President and Chief Accounting Officer (“CAO”) of Platform. In his role as CAO, Mr. Worshek will be the principal accounting officer of Platform and will report to Frank J. Monteiro, Chief Financial Officer of Platform. Mr. Worshek will also be an executive officer for reporting purposes under Section 16(a) of the Exchange Act. Prior to joining Platform, Mr. Worshek was the Chief Accounting Officer of SunTrust Banks, Inc. (NYSE:STI) from 2011 to 2013 and was employed by PricewaterhouseCoopers, LLP from 1997 to 2011. Mr. Worshek has a Bachelors of Science in Business Administration from the University of Nebraska at Omaha and a Masters of Business Administration from the Booth School of Business at the University of Chicago.

Concurrent with his appointment as CAO, Mr. Worshek was granted 15,000 RSUs that vest on the date on which Platform files its financial statements on Form 10-K for the year ended December 31, 2017, only if a certain EBITDA target is achieved for fiscal year 2017. The RSUs may, in certain circumstances, become immediately vested as of the date of a change in control of Platform. Each RSU represents a contingent right to receive one (1) share of Common Stock. A form of amended and restated RSU agreement of Platform is filed as Exhibit 10.5 hereto, and is incorporated herein by reference.

There is no arrangement or understanding between Mr. Worshek and any other person pursuant to which he was appointed as CAO. There has been no transaction, or proposed transaction, since January 1, 2013 to which Mr. Worshek or any member of his respective immediate family had or is to have a direct or indirect material interest or any other related transaction with the Company within the meaning of Item 404(a) of Regulation S-K. There are no family relationships between Mr. Worshek and any of the Company’s other directors, executive officers or persons nominated or chosen by the Company to become directors or executive officers.

Item 6. Exhibits

The following exhibits are filed as part of this Quarterly Report on Form 10-Q.

| Exhibit Number | Description |
|----------------|---|
| 2.1 | Agreement, dated as of August 4, 2014, among MacDermid Agricultural Solutions Holdings B.V., Platform Specialty Products Corporation, as guarantor, and a representative of Percival S.A. (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed on August 6, 2014, and incorporated herein by reference) |
| 3.1(a) | Certificate of Incorporation (filed as Exhibit 3.1 to the Company’s Post-Effective Amendment No. 1 to Form S-4 Registration Statement filed on January 24, 2014, and incorporated herein by reference) |
| 3.1(b) | Certificate of Amendment of Certificate of Incorporation (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 13, 2014, and incorporated herein by reference) |
| 3.2 | Amended and Restated By-laws (filed as Exhibit 3.2 to the Company’s Annual Report on Form 10-K, filed on March 31, 2014, and incorporated herein by reference) |
| 10.1 | Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Appendix A to Platform’s Definitive Proxy Statement, as filed on April 25, 2014, and incorporated herein by reference) |
| 10.2 | Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan (filed as Appendix B to Platform’s Definitive Proxy Statement, as filed on April 25, 2014, and incorporated herein by reference) |
| 10.3 | Amended and Restated Commitment Letter dated July 15, 2014, between Barclays Bank PLC and the Company (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 21, 2014, and incorporated herein by reference) |
| 10.4 | Registration Rights Agreement, dated May 20, 2014, between Platform, the placement agents thereto and the Investors stated therein (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 21, 2014, and incorporated herein by reference) |
| 10.5* | Form of Amended and Restated Restricted Stock Unit Agreement – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan |
| 31.1* | Principal Executive Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as Adopted Pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2* | Principal Financial Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as Adopted Pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1* | Principal Executive Officer and Principal Financial Officer Certifications Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| * 101** | The following materials from the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2014, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Operations for the three months ended June 30, 2014 and 2013, (ii) the Condensed Consolidated Statements of Comprehensive Income for the six months ended June 30, 2014 and 2013, (iii) the Condensed Consolidated Balance Sheets at June 31, 2014 and December 31, 2013, (iv) the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2014 and 2013, and (v) and Notes to the Condensed Consolidated Financial Statements. |

*Filed herewith.

**Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed furnished and not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act, are deemed furnished and not filed for purposes of Section 18 of the Exchange Act, and otherwise are not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized this August 6, 2014.

PLATFORM SPECIALTY PRODUCTS CORPORATION

By: /s/ Frank J. Monteiro
Name: Frank J. Monteiro
Title: Senior Vice President and Chief Financial Officer
(Principal Financial Officer)

EXHIBIT INDEX

| Exhibit Number | Description |
|----------------|---|
| 2.1 | Agreement, dated as of August 4, 2014, among MacDermid Agricultural Solutions Holdings B.V., Platform Specialty Products Corporation, as guarantor, and a representative of Percival S.A. (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed on August 6, 2014, and incorporated herein by reference) |
| 3.1(a) | Certificate of Incorporation (filed as Exhibit 3.1 to the Company's Post-Effective Amendment No. 1 to Form S-4 Registration Statement filed on January 24, 2014, and incorporated herein by reference) |
| 3.1(b) | Certificate of Amendment of Certificate of Incorporation (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 13, 2014, and incorporated herein by reference) |
| 3.2 | Amended and Restated By-laws (filed as Exhibit 3.2 to the Company's Annual Report on Form 10-K, filed on March 31, 2014, and incorporated herein by reference) |
| 10.1 | Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Appendix A to Platform's Definitive Proxy Statement, as filed on April 25, 2014, and incorporated herein by reference) |
| 10.2 | Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan (filed as Appendix B to Platform's Definitive Proxy Statement, as filed on April 25, 2014, and incorporated herein by reference) |
| 10.3 | Amended and Restated Commitment Letter dated July 15, 2014, between Barclays Bank PLC and the Company (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 21, 2014, and incorporated herein by reference) |
| 10.4 | Registration Rights Agreement, dated May 20, 2014, between Platform, the placement agents thereto and the Investors stated therein (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 21, 2014, and incorporated herein by reference) |
| 10.5* | Form of Amended and Restated Restricted Stock Unit Agreement – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan |
| 31.1* | Principal Executive Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as Adopted Pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2* | Principal Financial Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as Adopted Pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1* | Principal Executive Officer and Principal Financial Officer Certifications Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| * 101** | The following materials from the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2014, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Operations for the three months ended June 30, 2014 and 2013, (ii) the Condensed Consolidated Statements of Comprehensive Income for the six months ended June 30, 2014 and 2013, (iii) the Condensed Consolidated Balance Sheets at June 31, 2014 and December 31, 2013, (iv) the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2014 and 2013, and (v) and Notes to the Condensed Consolidated Financial Statements. |

*Filed herewith.

**Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed furnished and not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act, are deemed furnished and not filed for purposes of Section 18 of the Exchange Act, and otherwise are not subject to liability under these sections.

PLATFORM SPECIALTY PRODUCTS CORPORATION
AMENDED AND RESTATED
2013 INCENTIVE COMPENSATION PLAN
RESTRICTED STOCK UNIT AGREEMENT

FOR

1. **Award of Restricted Stock Units.** Platform Specialty Products Corporation (the “*Company*”) hereby grants, as of _____ (the “*Date of Grant*”), to _____ (the “*Recipient*”), the right to receive upon vesting as provided for herein, _____ restricted shares of the Company’s common stock (collectively the “*RSUs*”). The RSUs shall be subject to the terms, provisions and restrictions set forth in this Agreement and the Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (the “*Plan*”), which is incorporated herein for all purposes. As a condition to entering into this Agreement, and to the issuance of any Shares (or any other securities of the Company pursuant thereto), the Recipient agrees to be bound by all of the terms and conditions herein and in the Plan. Unless otherwise provided herein, terms used herein that are defined in the Plan and not defined herein shall have the meanings attributable thereto in the Plan.

2. **Vesting of RSUs.**

(a) **General Vesting.** Except as provided in Sections 2(c) and 3 of this Agreement, the RSUs shall vest on (the “*Vesting Date*”) the later of _____ or the date on which the Company files its financial statements on Form 10-K for the year ended December 31, _____ (the “*Measurement Year*”), if and only if the Committee determines that the Company’s EBITDA for the Measurement Year equals or exceeds \$ _____ (the “*EBITDA Target*”). Thus vesting of the RSU will depend on both time and the Company’s achievement of the specified EBITDA Target for the specified year.

(b) **Adjustments to Goals and Targets.**

(i) If, during the vesting period (i.e. the time between the Date of Grant and the Vesting Date), the Company or any of its Related Entities consummates (whether by merger, recapitalization, consolidation, stock purchase, asset purchase or otherwise) either an acquisition of any other company or business or a disposition of any material portion of the Company’s assets, in each case, out of the ordinary course of business, (an “*Acquired/Disposed Business*”), the Committee may determine, in its sole discretion, to adjust the EBITDA Target to account for the relative impact of the Acquired/Disposed Business. Notwithstanding the foregoing, if the Committee does not determine to adjust the EBITDA Target within thirty (30) days following the consummation of such transactions, the results of operations of the Acquired/Disposed Business shall be excluded from the determination of EBITDA and the EBITDA Target shall not be adjusted.

(ii) Adjustments that may be made by the Committee pursuant to this Agreement shall be made in accordance with the provisions and restrictions set forth in the Plan, and no adjustments shall be permitted if expressly prohibited in the Plan or may cause the RSUs to not satisfy the performance- based exception to Section 162(m) of the Code.

(c) **Acceleration of Vesting Upon Change in Control.** In the event that a Change in Control of the Company occurs during the Recipient's continuous service, except as provided in Section 3 hereof, the Shares subject to the RSUs under this Agreement shall become immediately vested as of the date of the Change in Control (the "**Change in Control Vesting Date**"), unless either (i) the Company is the surviving entity in the Change in Control and the RSUs continue to be outstanding after the Change in Control on substantially the same terms and conditions as were applicable immediately prior to the Change in Control or (ii) the successor company or its parent company assumes or substitutes for the RSUs, as determined in accordance with Section 10(c)(ii) of the Plan.

3. **Forfeiture of RSUs.**

(a) If the Recipient does not remain continuously actively employed by the Company for any reason prior to the earlier of (a) Vesting Date or (b) Change in Control Vesting Date, the RSUs granted hereunder shall be forfeited immediately upon such lapse in or termination of active service and the shares will be immediately canceled without recompense to or recourse by the Recipient.

(b) The Committee shall have the power and authority to enforce on behalf of the Company any rights of the Company under this Agreement in the event of the Recipient's forfeiture of RSUs pursuant to this Section 3.

4. **Settlement of the RSUs.** The Company shall deliver to the Recipient the number of Shares corresponding to the vested RSUs as soon as practicable on or after the Vesting Date or Change in Control Vesting Date, whichever applicable, but in no event later than the 15th day of the third month following the last day of the calendar year in which the Vesting Date or Change in Control Vesting Date, whichever applicable, occurs.

5. **Rights with Respect to RSUs.**

(a) **No Rights as Shareholder Until Delivery.** Except as otherwise provided in this Section 5, the Recipient shall not have any rights, benefits or entitlements with respect to the Shares corresponding to the RSUs unless and until those Shares are delivered to the Recipient (and thus shall have no voting rights, or rights to receive any dividend declared, before those Shares are so delivered). On or after delivery, the Recipient shall have, with respect to the Shares delivered, all of the rights of a holder of Shares granted pursuant to the articles of incorporation and other governing instruments of the Company, or as otherwise available at law.

(b) **Adjustments to Shares.** If at any time while this Agreement is in effect and before any Shares have been delivered with respect to any RSUs, there shall be any increase or decrease in the number of issued and outstanding Shares of the Company through the declaration of a stock dividend or through any recapitalization resulting in a stock split-up, combination or exchange of such Shares, then and in that event, the Committee (or Board as applicable) may make any adjustments it deems fair and appropriate, in view of such change, in the number of Shares subject to the RSUs then subject to this Agreement. If any such adjustment shall result in a fractional Share, such fraction shall be disregarded.

(c) **Restriction on Certain Transactions.** Notwithstanding any term or provision of this Agreement to the contrary, the existence of this Agreement, or of any outstanding RSUs awarded hereunder, shall not affect in any manner the right, power or authority of the Company or any Related Entity to make, authorize or consummate: (i) any or all adjustments, recapitalizations, reorganizations or other changes in the Company's or any Related Entity's capital structure or its business; (ii) any merger, consolidation or similar transaction by or of the Company or any Related Entity; (iii) any offer, issue or sale by the Company or any Related Entity of any capital stock of the Company or any Related Entity, including any equity or debt securities, or preferred or preference stock that would rank prior to or on parity with the Shares represented by the RSUs and/or that would include, have or possess other rights, benefits and/or preferences superior to those that such Shares includes, has or possesses, or any warrants, options or rights with respect to any of the foregoing; (iv) the dissolution or liquidation of the Company or any Related Entity; (v) any sale, transfer or assignment of all or any part of the stock, assets or business of the Company or any Related Entity; or (vi) any other corporate transaction, act or proceeding (whether of a similar character or otherwise).

6. **Transferability.** The RSUs are not transferable unless and until the Shares have been delivered to the Recipient in settlement of the RSUs in accordance with this Agreement, otherwise than by will or under the applicable laws of descent and distribution. The terms of this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Recipient. Except as otherwise permitted pursuant to the first sentence of this Section, any attempt to effect a Transfer of any RSUs prior to the date on which the Shares have been delivered to the Recipient in settlement of the RSUs shall be void *ab initio*. For purposes of this Agreement, "Transfer" shall mean any sale, transfer, encumbrance, gift, donation, assignment, pledge, hypothecation, or other disposition, whether similar or dissimilar to those previously enumerated, whether voluntary or involuntary, and including, but not limited to, any disposition by operation of law, by court order, by judicial process, or by foreclosure, levy or attachment.

7. **Tax Matters.**

(a) **Withholding.** As a condition to the Company's obligations with respect to the RSUs (including, without limitation, any obligation to deliver any Shares) hereunder, the Recipient shall make arrangements satisfactory to the Company to pay to the Company any federal, state or local taxes of any kind required to be withheld with respect to the delivery of Shares corresponding to such RSUs. If the Recipient shall fail to make the tax payments as are required, the Company shall, to the extent permitted by law, have the right to deduct from any payment of any kind (including the withholding of any Shares that otherwise would be delivered to Recipient under this Agreement) otherwise due to the Recipient any federal, state or local taxes of any kind required by law to be withheld with respect to such Shares.

(b) **Satisfaction of Withholding Requirements.** The Recipient may satisfy the withholding requirements with respect to the RSUs pursuant to any one or combination of the following methods:

(i) payment in cash; or

(ii) if and to the extent permitted by the Committee, payment by surrendering unrestricted previously held Shares which have a value equal to the required withholding amount or the withholding of Shares that otherwise would be deliverable to the Recipient pursuant to this Agreement. The Recipient may surrender Shares either by attestation or by delivery of a certificate or certificates for Shares duly endorsed for transfer to the Company, and if required with medallion level signature guarantee by a member firm of a national stock exchange, by a national or state bank (or guaranteed or notarized in such other manner as the Committee may require).

(c) **Recipient's Responsibilities for Tax Consequences.** The tax consequences to the Recipient (including without limitation federal, state, local and foreign income tax consequences) with respect to the RSUs (including without limitation the grant, vesting and/or delivery thereof) are the sole responsibility of the Recipient. The Recipient shall consult with his or her own personal accountant(s) and/or tax advisor(s) regarding these matters and the Recipient's filing, withholding and payment (or tax liability) obligations.

8. **Amendment, Modification & Assignment.** This Agreement may only be modified or amended in a writing signed by the parties hereto. No promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, with respect to the subject matter hereof, have been made by either party which are not set forth expressly in this Agreement. Unless otherwise consented to in writing by the Company, in its sole discretion, this Agreement (and Recipient's rights hereunder) may not be assigned, and the obligations of Recipient hereunder may not be delegated, in whole or in part. The rights and obligations created hereunder shall be binding on the Recipient and his heirs and legal representatives and on the successors and assigns of the Company.

9. **Complete Agreement.** This Agreement (together with those agreements and documents expressly referred to herein, for the purposes referred to herein) embodies the complete and entire agreement and understanding between the parties with respect to the subject matter hereof, and supersedes any and all prior promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, which may relate to the subject matter hereof in any way.

10. **Miscellaneous.**

(a) **No Right to (Continued) Employment or Service.** This Agreement and the grant of RSUs hereunder shall not confer, or be construed to confer, upon the Recipient any right to employment or service, or continued employment or service, with the Company or any Related Entity.

(b) **No Limit on Other Compensation Arrangements.** Nothing contained in this Agreement shall preclude the Company or any Related Entity from adopting or continuing in effect other or additional compensation plans, agreements or arrangements, and any such plans, agreements and arrangements may be either generally applicable or applicable only in specific cases or to specific persons.

(c) **Severability.** If any term or provision of this Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or under any applicable law, rule or regulation, then such provision shall be construed or deemed amended to conform to applicable law (or if such provision cannot be so construed or deemed amended without materially altering the purpose or intent of this Agreement and the grant of RSUs hereunder, such provision shall be stricken as to such jurisdiction and the remainder of this Agreement and the award hereunder shall remain in full force and effect).

(d) **No Trust or Fund Created.** Neither this Agreement nor the grant of RSUs hereunder shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Related Entity and the Recipient or any other person. To the extent that the Recipient or any other person acquires a right to receive payments from the Company or any Related Entity pursuant to this Agreement, such right shall be no greater than the right of any unsecured general creditor of the Company.

(e) **Law Governing.** This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware (without reference to the conflict of laws rules or principles thereof).

(f) **Interpretation.** The Recipient accepts this award of RSUs subject to all of the terms, provisions and restrictions of this Agreement and the Plan. The undersigned Recipient hereby accepts as binding, conclusive and final all decisions or interpretations of the Board or the Committee upon any questions arising under this Agreement or the Plan.

(g) **Headings.** Section, paragraph and other headings and captions are provided solely as a convenience to facilitate reference. Such headings and captions shall not be deemed in any way material or relevant to the construction, meaning or interpretation of this Agreement or any term or provision hereof.

(h) **Notices.** Any notice under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or when deposited in the United States mail, registered, postage prepaid, and addressed, in the case of the Company, to the Company's Secretary at 245 Freight Street, Waterbury, Connecticut 06702, or if the Company should move its principal office, to such principal office, and, in the case of the Recipient, to the Recipient's last permanent address as shown on the Company's records, subject to the right of either party to designate some other address at any time hereafter in a notice satisfying the requirements of this Section.

(i) **Compliance with Section 409A**

(i) **General.** It is the intention of both the Company and the Recipient that the benefits and rights to which the Recipient could be entitled pursuant to this Agreement either comply with or fall within an exception to Section 409A of the Code and the Treasury Regulations and other guidance promulgated or issued thereunder (“**Section 409A**”), to the extent that the requirements of Section 409A are applicable thereto, and the provisions of this Agreement shall be construed in a manner consistent with that intention.

(ii) **No Representations as to Section 409A Compliance.** Notwithstanding the foregoing, the Company does not make any representation to the Recipient that the shares of RSUs awarded pursuant to this Agreement are exempt from, or satisfy, the requirements of Section 409A, and the Company shall have no liability or other obligation to indemnify or hold harmless the Recipient or any Beneficiary for any tax, additional tax, interest or penalties that the Recipient or any Beneficiary may incur in the event that any provision of this Agreement, or any amendment or modification thereof or any other action taken with respect thereto is deemed to violate any of the requirements of Section 409A.

(iii) **No Acceleration of Payments.** Neither the Company nor the Recipient, individually or in combination, may accelerate any payment or benefit that is subject to Section 409A, except in compliance with Section 409A and the provisions of this Agreement, and no amount that is subject to Section 409A shall be paid prior to the earliest date on which it may be paid without violating Section 409A.

(j) **Non-Waiver of Breach.** The waiver by any party hereto of the other party's prompt and complete performance, or breach or violation, of any term or provision of this Agreement shall be effected solely in a writing signed by such party, and shall not operate nor be construed as a waiver of any subsequent breach or violation, and the waiver by any party hereto to exercise any right or remedy which he or it may possess shall not operate nor be construed as the waiver of such right or remedy by such party, or as a bar to the exercise of such right or remedy by such party, upon the occurrence of any subsequent breach or violation.

(k) **Counterparts.** This Agreement may be executed in two or more separate counterparts, each of which shall be an original, and all of which together shall constitute one and the same agreement.

(l) **Clawback of Benefits.** The Company may (i) cause the cancellation of the RSUs, (ii) require reimbursement of any benefit conferred under the RSUs to the Recipient or Beneficiary, and (iii) effect any other right of recoupment of equity or other compensation provided under the Plan or otherwise in accordance with any Company policies that currently exist or that may from time to time be adopted or modified in the future by the Company and/or applicable law (each, a “**Clawback Policy**”). In addition, the Recipient may be required to repay to the Company certain previously paid compensation, whether provided under the Plan or an Award Agreement or otherwise, in accordance with any Clawback Policy. By accepting this Award, the Recipient agrees to be bound by any existing or future Clawback Policy adopted by the Company, or any amendments that may from time to time be made to the Clawback Policy in the future by the Company in its discretion (including without limitation any Clawback Policy adopted or amended to comply with applicable laws or stock exchange requirements) and further agrees that all of the Recipient's Award Agreements (and/or awards issued under the Prior Plan) may be unilaterally amended by the Company, without the Recipient's consent, to the extent that the Company in its discretion determines to be necessary or appropriate to comply with any Clawback Policy.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the _____ day of _____ .

COMPANY:
PLATFORM SPECIALTY PRODUCTS
CORPORATION, a Delaware corporation

By: _____
Name:
Title:

The Recipient acknowledges receipt of a copy of the Plan and represents that he or she has reviewed the provisions of the Plan and this Agreement in their entirety, is familiar with and understands their terms and provisions, and hereby accepts this RSU award subject to all of the terms and provisions of the Plan and the Agreement. The Recipient further represents that he or she has had an opportunity to obtain the advice of counsel prior to executing this Agreement.

Dated: _____

RECIPIENT:

**Certification of Principal Executive Officer
Pursuant to Section 302 of Sarbanes-Oxley Act of 2002**

I, Daniel H. Leever, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Platform Specialty Products Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) (paragraph omitted pursuant to Rule 13a-14(a) of the General Rules and Regulations promulgated under the Securities Exchange Act of 1934);
 - (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's independent auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 6, 2014

/s/ Daniel H. Leever
Daniel H. Leever
Chief Executive Officer, President and Vice Chairman

**Certification of Principal Financial Officer
Pursuant to Section 302 of Sarbanes-Oxley Act of 2002**

I, Frank J. Monteiro, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Platform Specialty Products Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) (paragraph omitted pursuant to Rule 13a-14(a) of the General Rules and Regulations promulgated under the Securities Exchange Act of 1934);
 - (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's independent auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 6, 2014

/s/ Frank J. Monteiro
Frank J. Monteiro
Senior Vice President and Chief Financial Officer

**CERTIFICATION
OF
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Daniel H. Leever, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Platform Specialty Products Corporation on Form 10-Q for the fiscal quarter ended June 30, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Platform Specialty Products Corporation.

Date: August 6, 2014

By: /s/ Daniel H. Leever
Name: Daniel H. Leever
Title: Chief Executive Officer, President and Vice Chairman

I, Frank J. Monteiro, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Platform Specialty Products Corporation on Form 10-Q for the fiscal quarter ended June 30, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Platform Specialty Products Corporation.

Date: August 6, 2014

By: /s/ Frank J. Monteiro
Name: Frank J. Monteiro
Title: Senior Vice President and Chief Financial Officer